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 Systemic lupus erythematosus is an autoinflammatory disorder driven by 
the development of autoantibodies to self-nucleic acids, in particular to DNA and 
to chromatin. Loss-of-function mutations of the secreted deoxyribonuclease 
DNASE1L3 have been implicated in the development of aggressive familial lupus. 
In addition, recent genome-wide association studies have linked a hypomorphic 
variant of DNASE1L3 to sporadic lupus. Studies in the lab determined that 
Dnase1l3-deficient mice develop rapid autoantibody responses against dsDNA 
and chromatin, and at older ages this leads to a lupus-like inflammatory disease. 
These disease manifestations were completely independent of the intracellular 
DNA sensor STING, which has been implicated in other examples of self-DNA 
driven autoinflammatory diseases. My project focused on developing assays to 
track the activity of DNASE1L3, as well as identifying the endogenous source of 
self-DNA normally processed by DNASE1L3. Using mouse models that allow the 
depletion of specific cell populations, we found that circulating DNASE1L3 is 
produced by hematopoietic cells, in particular by CD11c+ dendritic cells and by 
tissue macrophages. Taking into account the unique properties of DNASE1L3, 
we discovered that this enzyme is uniquely able to digest chromatin contained 
within and on the surface of apoptotic microparticles. Loss of DNASE1L3 activity 
 
in circulation results in elevated levels of DNA in plasma, in particular within 
microparticles. Microparticles are extensively bound by anti-chromatin 
autoantibodies isolated from both murine models of lupus as well as prototypical 
human clones. In addition, Dnase1l3-deficient mice have high levels of circulating 
IgG that bind to microparticles from young ages, and these titers increased as 
disease progressed in aged animals. Pretreatment of microparticles with 
DNASE1L3 largely abrogated this binding, demonstrating that DNASE1L3 
directly reduces the immunogenicity of microparticles. We also studied two 
human patients with null mutations in DNASE1L3, and observed increased DNA 
circulating in plasma and, in particular, in their microparticles, demonstrating a 
conserved role for DNASE1L3 in mice and humans. Finally, we obtained plasma 
samples from a cohort of patients with sporadic SLE, and found that roughly 80% 
had circulating IgG that avidly bound microparticles. Roughly half of this group 
failed to bind to microparticles that had been pretreated with DNASE1L3, and this 
DNASE1L3-sensitive group also presented with lower levels of DNASE1L3 
activity. We conclude that extracellular chromatin associated with microparticles 
acts as a potential self-antigen capable of causing loss of tolerance to self-DNA 
and inflammatory disease in both mice and humans. The secretion of a DNA-
processing enzyme thus represents a novel, conserved tolerogenic mechanism 
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Introduction 
 
Systemic lupus erythematosus: prevalence and therapeutic options 
 Systemic lupus erythematosus (SLE or lupus) is an autoinflammatory 
disease wherein pathogenesis is driven by the production of antibodies (Abs) to 
self-nuclear antigens. Targets may include ribonucleoproteins and/or nucleic 
acids. Following the initial loss of tolerance, auto-Ab production amplifies further 
inflammatory responses via the innate immune system, resulting in the activation 
of myeloid pathways and the production of type 1 interferon (interferon /, IFN) 
(1). In turn, the production of auto-Abs is dramatically enhanced by these 
inflammatory molecules, resulting in a feed forward pathogenic loop (1). Immune 
complexes are then formed by these auto-Abs and nucleic acids, and upon their 
deposition in various tissues cause chronic inflammation, including arthritis, 
vasculitis, and glomerulonephritis (1). An additional aspect of SLE pathogenesis 
is its unpredictable flaring, the causes of which vary considerably between 
patients (1, 2). Known triggers include but are not limited to pregnancy (3), viral 
or bacterial infection (4), ultraviolet radiation (5), stress (6), and exposure to 
various environmental agents including pharmaceuticals, chemicals, or food 
products (7). 
 Current estimates as to the prevalence of SLE range from 20-150 cases 
per 100,000 persons (2). Like most complex inflammatory disorders, there are 
numerous genetic and environmental factors that have been linked to SLE 
development. Indeed, studies have shown that the concordance for SLE among 
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monozygotic twins is approximately 24% (8). In addition, there is strong evidence 
for involvement of the endocrine system in SLE, as roughly 90% of patients are 
female (9). Furthermore, rates of SLE dramatically differ depending on ethnicity, 
with African Americans being a particularly vulnerable population for reasons 
unknown. Consequently, among African American women the rate is over 400 
cases per 100,000 persons (10). 
 Because the presentation of SLE can vary wildly between patients, or, 
indeed, between flares of a single individual, its identification and assessment 
can be challenging. Currently, there are two main scoring systems for SLE 
patients: the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 
and the American College of Rheumatology (ACR) criteria (11, 12). Both 
ultimately evaluate patients based on the presence or absence of a wide variety 
of symptoms, ranging from neurological (psychosis, seizures, sensory or motor 
neuropathy, etc.) to hematological (anemia, leukopenia, thrombocytopenia) to 
immunological (presence of auto-antibodies). Importantly, not every symptom 
has to be present to result in a diagnosis of SLE; of the 11 ACR criteria the 
presence of at 4 yields a sensitivity of 85% and a specificity of 95% for SLE (12). 
SLEDAI scores, alternatively, are used to monitor patients longitudinally, as 
fluctuations in score play a major role in determining changes to the course of 
treatment. 
 Despite the high (and increasing) prevalence of SLE, therapeutic options 
remain inadequate. Because little is known regarding the mechanisms driving 
loss of tolerance in SLE, current treatments are limited to the treatment of 
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symptoms rather than the underlying pathology (13). Widely used strategies 
include over the counter or prescription nonsteroidal anti-inflammatory drugs 
(NSAIDs), the anti-malarial drug hydroxychloroquine, prednisone or other 
corticosteroids, and, in severe cases, immunosuppression with 
chemotherapeutics such as methotrexate (13, 14). These therapies all represent 
broad anti-inflammatory interventions that fail to address the specific dysfunction 
of normal immune pathways driving SLE. Furthermore, there are few effective 
therapies in development; indeed, there has been only one new drug 
successfully developed and approved by the FDA for the treatment of SLE in the 
past 60 years (15). 
 
Pathogenesis of SLE: cells and cytokines 
 At the macro level, both branches of the immune system play essential 
roles in the development of SLE. The innate immune system contributes both in 
the early and late stages of the disease. Initially, myeloid populations such as 
dendritic cells activate T cells and produce B-cell activating factor (BAFF), which 
drives the adaptive response (16). Activated T lymphocytes, specifically TH1 and 
TH17 helper populations then drive the systemic and renal activation of B cells 
(17-19). B cell activation results in the production of anti-nuclear antigen (ANA) 
autoantibodies, which form immune complexes and are deposited throughout the 
body in various tissues, causing inflammation and pathogenesis via the activation 
of localized innate pathways (19, 20). Deposition of these autoantibody 
complexes at different sites in the body account for the variation in symptoms 
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between individuals and/or flares (21). Thus, the activation of autoreactive B cells 
and their subsequent release of autoantibodies represents the central hallmark of 
SLE.  
 While the primary cause of SLE is the deposition of immune complexes, 
deregulation of inflammatory cytokines is a major contributor to immune 
dysfunction and ultimately tissue injury. Inflammatory cytokines, such as type I 
and type II interferons (IFNs), interleukin (IL)-6, IL-1, and tumor necrosis factor-
alpha (TNF), have all been implicated in the pathogenesis of SLE (22-27). 
Furthermore, immunomodulatory cytokines have also shown to play roles in 
preventing SLE, including IL-10 (28) and transforming growth factor-beta (TGF) 
(29). Finally and more broadly, regulatory T cells play an important role in limiting 
deleterious autoinflammatory conditions such as lupus, as shown by recent 
studies linking IL-21, IL-17, and IL-2 to SLE (30). 
 Work from the group of Virginia Pascual has shown that SLE patients 
frequently present with an enhanced type I IFN signature (31). Type I IFNs can 
have extensive systemic effects at multiple levels that contribute to SLE 
pathogenesis. Firstly, IFN promotes positive feedback loops, enhancing the 
synthesis of additional type I IFN via the induction of Toll-like receptor (TLR) 7 
(32). Secondly, IFNs drive the maturation of dendritic cells (DCs), shifting the 
balance of immature versus mature DCs (33). Crucially, immature DCs are 
important in maintaining regulatory T cells in the periphery, and also help 
promote deletion of autoreactive T cells by presenting self-antigens in the 
absence of costimulatory molecules (33). Thirdly, mature DCs produce BAFF, 
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which directly enhances the selection and survival of autoreactive B cells (34). 
Finally, IFN both enhances the cytotoxic capabilities of CD8 T cells (35) and 
also increases the number of autoreactive CD4 T cells by driving the upregulated 
expression of CD80 and CD86 on APCs (33). 
 IL-6 is a proinflammatory cytokine that, in SLE, acts primarily at the level 
of B cells and T cells. It has been shown to play a key role in driving the 
hyperactivation of B cells (36) and in promoting autoreactive T cell responses 
(37). In mouse models of rheumatoid arthritis, IL-6 has been shown to be vital for 
the differentiation of TH17 helper cells (38), a proinflammatory population that has 
also been implicated in the pathogenesis of SLE (18). Finally, IL-6 has been 
shown to play important roles in mediating local inflammatory responses in lupus 
patients. Elevated IL-6 is found in the kidneys of patients presenting with lupus 
nephritis (39), as well as in the cerebrospinal fluid of patients presenting with 
neuropsychiatric complications (40). 
 IFN-gamma (IFN) is the primary cytokine that drives TH1 responses. In 
other contexts, TH1 responses have been shown to counteract aberrant 
autoinflammatory reactions, largely thought to be because they inhibit the 
development of autoreactive TH17 cells (41). However, in the context of lupus it 
has been shown to induce production of IgG2a isotype antibodies, which can 
contribute to autoimmunity by the activation of the complement system (42). 
Lupus-prone mice deficient for IFN present with an ameliorated form of the 
disease (43), and in human patients it has been suggested that an imbalance in 
favor of TH1 responses can drive disease (44). However, additional clinical 
 
 - 6 - 
studies have proved inconclusive, with some suggesting that levels of IFN are 
tied closely to the severity of lupus nephritis (45), while others observe no 
correlation (46). Although these data are not clear cut, what is apparent is that if 
IFN plays a role in SLE pathogenesis, it is likely in exacerbating disease after 
the initial loss of tolerance. 
 In addition to the overproduction of proinflammatory cytokines, SLE can 
be exacerbated by disruption of regulatory cytokine production. Lupus-prone 
mice that also lack IL-10 develop a more severe form of the disease (28). IL-10 
acts to dampen proinflammatory responses, including but not limited to TH1 
helper cells, TH17 helper cells, and macrophages, making it a key molecule in 
preventing autoimmunity (47). Along these lines, TGF- is strikingly reduced in 
lupus patients undergoing active disease (29). TGF- also plays an 
immunosuppressive role, particularly via modulation of lymphocyte activation and 
differentiation (48). Reductions in TGF- lead to a loss of regulatory T cells in the 
periphery and an overall increase in inflammatory profile, providing a permissive 
environment for autoreactive responses (48). 
 IL-23 and IL-17 act synergistically to drive the differentiation of TH17 
helper cells, which as previously discussed are a potent proinflammatory subtype. 
These cells are generally balanced by the presence of regulatory T cells, which 
produce anti-inflammatory cytokines and prevent autoimmunity. IL-2, produced 
by other T cells, is a critical growth factor for regulatory T cells in particular. 
Lower levels of IL-2 lead to a striking reduction in their population (49), and a 
corresponding increase in TH17 cells (50). The T cells of active SLE patients 
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produce less IL-2 compared to controls (51), and patients also present with a 
reduced population of regulatory T cells (52). Thus, perturbing the balance of 
proinflammatory versus regulatory T cells correlates with SLE severity, indicating 
complex and opposing roles for these populations.  
 
Mouse models of SLE and their applicability to human disease 
 One major factor that has drastically hampered understanding of human 
SLE pathogenesis and consequently drug development is the lack of 
representative mouse models. The oldest and most widely used model is the 
New Zealand Black/New Zealand White (NZB/NZW) F1 hybrid, which 
spontaneously develops lupus-like symptoms such as lymphadenopathy, 
splenomegaly, and ANA autoantibodies whose repertoire includes anti-DNA (53, 
54). These anti-double stranded DNA (dsDNA) antibodies typically lead to 
glomerulonephritis and eventually fatal kidney failure (53, 54). Additional study of 
these mice led to the identification of three genetic loci that, when all were 
present in combination, drove the development of lupus-like disease in these 
mice, dubbed Sle1-3 (55). Unfortunately, due to the requirement for all three loci 
to be present, extensive genetic studies using this model are extremely 
challenging and, generally, unfeasible. Furthermore, in stark contrast to many 
human patients where anti-DNA antibodies are detectable prior to the 
development of overt symptoms (56), NZB/NZW mice develop autoantibodies 
against DNA slowly, and typically only after extensive immune activation (57). 
Ultimately, this suggests that while anti-dsDNA antibodies may play a role in the 
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ongoing pathogenesis of these animals, loss of tolerance to DNA is unlikely to be 
the initial insult driving SLE development. 
 An alternative model was subsequently discovered. A substrain of the 
inbred MRL line was characterized that developed a sex-independent SLE-like 
disease characterized by lymphadenopathy driven by double negative immature 
T cells (58). These mice also presented with high levels of circulating immune 
complexes driven by ANA IgG, including high anti-dsDNA (58). Ultimately, this 
phenotype was attributed to an autosomal recessive mutation in the Fas receptor, 
dubbed lymphoproliferation (lpr). Mice harboring this mutation are deficient for 
Fas activity, which dramatically impairs apoptosis in lymphocytes (59). This 
defect in negative selection of autoreactive cells is sufficient to drive the 
development of lupus-like disease. Crucially however, subsequent studies 
demonstrated that mice positive for the lpr mutation from other strains were 
asymptomatic, indicating vital roles for genes specific for the MRL background 
(60). Thus, the requirement for a specific background represents a significant 
obstacle for in depth genetic analysis. In addition, the lpr model suffers from the 
same issue of specificity as the NZB/NZW mice, namely that loss of tolerance to 
DNA is a consequence of inappropriate immune activation and is not driving 
pathogenesis. 
 Further efforts to pinpoint a monogenic model of disease led to the 
identification of the BXSB mouse strain, derived from the F1 intercross between 
C57BL6 and SB/Le strains and subsequent backcrossing onto SB/Le (54). These 
mice developed lupus-like disease that, curiously, was much more severe in 
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males, and further study identified the presence of the Y-linked autoimmune 
accelerator (Yaa) genetic element (61, 62). It was subsequently discovered that 
this element is due to a translocation of a portion of the X chromosome to the Y 
chromosome, resulting in the duplication of several genes and a 2-fold increase 
in expression (63, 64). Crucially, one of these duplicated genes is TLR7, which 
encodes an innate pattern recognition receptor specific for viral ssRNA (63-66). 
Activation of TLR7 results in signaling through myeloid differentiation primary 
response gene 88 (MyD88), leading to the activation of proinflammatory 
pathways in DCs and B cells (67, 68). Importantly, signaling through TLR7 has 
been shown to act as a second signal in B cells, allowing for activation of 
autoreactive cells upon interactions with endogenous RNA ligands (69, 70). 
Consequently, TLR7-transgenic mice have become a widely-used model to study 
SLE (32, 63, 66, 67, 71, 72) and further analysis has revealed that 
polymorphisms in TLR7 are linked to human disease in certain populations (65, 
73). 
However, this model does have drawbacks. Disease in TLR7-transgenic 
animals is primarily driven by loss of tolerance to various forms of self-RNA (32, 
63, 67), but in human disease anti-DNA antibodies are more pathogenic and 
predictive of disease outcomes (56, 74). An additional complication stems from 
the mechanism by which TLR7 is regulated. The endosomal TLRs (TLR7, TLR9, 
and TLR3) are produced in the endoplasmic reticulum and are dependent on the 
chaperone protein Unc-93 homolog B1 (UNC93B1) for trafficking to endosomes 
(75). Consequently, changes in the expression level of one endosomal TLR also 
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affect the availability of UNC93B1, meaning that TLR7 transgenic mice also 
present with reduced levels of endosomal TLR9 (71). Importantly, loss of TLR9 
has been linked to exacerbation of autoimmunity (76), and it is unclear if this is 
due to increases in TLR7 or if TLR9 has additional immunomodulatory functions. 
A final downside of this model is that TLR7 is sufficient to drive disease only at 
very high doses, as the two-fold increase caused by Yaa translocation requires 
the presence of additional susceptibility loci for overt autoimmune disease (77). 
Thus, the requirement for high levels of TLR7 complicates genetic analysis and 
the extent to which it mimics human disease broadly is unclear. 
In addition to genetic models of SLE, exposure to environmental triggers 
has been used to induce the disease independently of mouse background. Chief 
among these is the pristane-induced lupus model, which is driven by 
intraperitoneal injections of pristane (2,6,10,14-tetramethylpentadecane) into 
mice on a BALB/c background (78, 79). These mice develop autoantibodies 
characteristic of lupus, including anti-histone, anti-ribonucleoprotein, and anti-
DNA variants, generally presenting with similar repertoires and disease 
progression as MRL/lpr mice (78, 79). Additional mouse backgrounds have 
subsequently been tested, and develop autoantibodies in response to pristane 
injection to varying extents (80). Although this model is again not driven by loss 
of tolerance to DNA specifically, it has proved useful in determining whether 
various inflammatory pathways contribute to lupus pathogenesis. For instance, 
injection of pristane into mice deficient for IL-6 demonstrated the importance of 
this cytokine for the development of anti-DNA autoantibodies (23). Additionally, 
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pristane injection into mice deficient for IFN-I receptor (IFNAR) led to extensive 
but not total ablation of the disease (81, 82), which corresponds with studies 
linking overexpression of interferon with disease severity in human patients (83-
85). One key difference, however, is that whereas in humans plasmacytoid 
dendritic cells (pDCs) are the key producers of interferon (86), in the pristane-
induced mouse model it is produced by Ly6Chi monocytes that aggregate in the 
peritoneal cavity (87). Furthermore, interferon production by these cells requires 
the presence of TLR7, again suggesting that there is no loss of tolerance to DNA 
specifically in this model (88). 
Thus, there is a critical need for the development of a monogenic mouse 
model that presents with extensive anti-DNA responses before proceeding to 
disease. While some of the aforementioned mouse models feature these 
autoantibodies to varying extents, none of these models recapitulate loss of 
tolerance to self-DNA. Modeling anti-DNA responses is important because high 
affinity IgG specific for dsDNA are especially pathogenic and have been 
demonstrated to correlate with the severity of symptoms in human disease, in 
particular glomerulonephritis and kidney injury (56, 74, 83, 89). Furthermore, loss 
of tolerance to self-DNA seems to be a key event leading to the development of 
sporadic disease, as many patients present with high levels of anti-DNA 
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Genetics of SLE 
 SLE in humans typically falls into one of two categories: sporadic disease 
and familial (or monogenic) disease. Inherited SLE is very rare, and in humans 
has been definitively linked to only a small number of genes, all of which are 
involved in cell death pathways or in the clearance of apoptotic debris (90). In the 
study of sporadic disease, numerous genome wide association studies (GWAS) 
have identified more than 50 common risk loci for SLE susceptibility. 
Unsurprisingly, the strongest association signal among common SLE variants is 
obtained from the HLA region (90). Other genes implicated generally fall into four 
different categories: activation of the adaptive immune system, innate immune 
signaling, renal-specific factors, and clearance of self-nucleic acids (91). Genes 
affecting activation of the adaptive system include those that modulate B cell 
receptor signaling (92), T and B cell crosstalk via MHC (93), and the 
differentiation of T cells into various effector phenotypes (94). Innate signaling 
pathways known to be dysregulated include the type I IFNs (95), immunoglobulin 
Fc receptors (96), and various molecules upstream of nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-B) (97). Renal-specific factors include 
localized activation of myeloid cells or lymphocytes (98, 99), clearance of 
immune complexes from glomeruli (100), and potential disease pathways active 
in resident renal cells, such as angiotensin-converting enzyme (ACE) (101). The 
last category of molecules implicated by GWAS are predominantly involved in the 
processing of self-antigens, and includes the complement system (102) and the 
clearance of apoptotic cells (103). 
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Identifying the antigenic form of self-DNA driving pathogenesis in SLE 
 In addition, a major outstanding question in the field concerns the nature 
of antigenic self-DNA that drives loss of tolerance. Despite extensive efforts, it 
remains unclear which specific form of self-DNA is recognized by autoreactive B 
cells, although different types of self-DNA have been implicated in SLE 
pathogenesis such as oxidized mitochondrial DNA and neutrophil extracellular 
traps (104-107). Mitochondria are organelles present in all nucleated cells, and 
contain their own DNA, packaged into structures called nucleoids (108). Because 
mitochondria are the site of oxidative phosphorylation in the body, they 
accumulate large quantities of reactive oxygen species, leading to a high rate of 
mutations due to oxidation of their DNA and the lack of proofreading DNA repair 
machinery (108). In lupus patients, neutrophils accumulate this oxidized 
mitochondrial DNA as a consequence of impaired nucleoid digestion, and this 
DNA is instead extruded into the extracellular space (104). Oxidized 
mitochondrial DNA is both a potent stimulator of interferon and a target of 
autoantibodies in these individuals, as it is recognized by TLR9 in pDCs (104, 
107). 
 In addition, oxidized mitochondrial DNA can be incorporated into 
neutrophil extracellular traps (NETs) (107). NETs are composed of processed 
self-DNA bound to various cytoplasmic proteins that are then organized into large 
filamentous structures (109). NET generation occurs via a specific form of cell 
death called NETosis, wherein fragmentation of the nucleus results in the 
availability of chromatin to be integrated and released in NETs (109). These 
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structures play key antimicrobial roles, both via direct binding to pathogens (110) 
and by delivery of high local concentrations of antimicrobial peptides (111). 
Importantly, they also play a role in the inactivation of virulence factors via the 
delivery of intracellular enzymes, such as elastase (109). Furthermore, they act 
to contain microbes at the initial site of infection, preventing dissemination (109). 
However, because NETs contain abundant self-DNA, they have been linked to 
the development of autoimmunity, in particular through activation of TLR9 (105, 
106). Thus, although both oxidized mitochondrial DNA and NETs may act as 
second signals, it is unclear whether they are capable of functioning as antigens 
for DNA-specific autoreactive B cells. 
 
Vital roles for deoxyribonucleases in the prevention of autoimmunity 
 The existence of nucleic acid-sensing innate immune receptors presents a 
fundamental problem for the body, given the abundance of self-DNA and the 
limited capacity for structural differences been self and non-self nucleic acids. 
This paradigm is addressed by the vitally important processing of self-DNA so as 
to render it non-immunogenic. This function is performed by a class of enzymes 
called deoxyribonucleases (DNASEs), which catalyze the hydrolytic cleavage of 
DNA phosphodiester linkages. These fall into three broad categories, DNASE1 
and the DNASE1-like family members, DNASE2, and DNASE3, which is also 
known as three-prime repair exonuclease 1 (TREX1). 
 DNASE2 is expressed at high levels in phagocytic cells, in particular 
macrophages, and is responsible for the digestion of DNA accumulated in 
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lysosomes (112). Its potent activity is regulated by the requirement for activation 
by low pH and cleavage by lysosomal proteases (113). DNASE2 plays important 
roles in the digestion of DNA from apoptotic cells and also nuclei extruded from 
erythrocytes, both of which are normally engulfed by phagocytes (114). This 
function is absolutely vital, as mice deficient for DNASE2 die during embryonic 
development due to massive production of interferon triggered by undigested 
self-DNA (115, 116). Mice doubly deficient for both DNASE2 and IFNAR were 
viable, though did develop chronic polyarthritis that resembled human 
rheumatoid arthritis, driven in part by the leaking of DNA from lysosomes into the 
cytoplasm (116). It was subsequently discovered that recognition of accumulated 
self-DNA by the cytosolic DNA sensor and adaptor protein Stimulator of 
interferon genes (STING) was responsible for driving autoimmunity in this model, 
as mice lacking both DNASE2 and STING were both viable and completely failed 
to develop arthritis (117). STING activates the transcription factor IFN regulatory 
factor 3 (IRF3), leading to the production of IFN and other inflammatory 
chemokines (118). It remains unclear what upstream mechanisms are 
responsible for activation of STING in this context. STING is commonly triggered 
by the presence of cyclic 2’-5’ 3’-5’ GMP-AMP dinucleotides (cGAMP) produced 
by cyclic GMP-AMP synthase (cGAS) (119). However, double deficiency of both 
cGAS and DNASE2 failed to rescue the inflammatory phenotype despite the 
accumulation of cGAMP in DNASE2 knockout mice (120), suggesting that there 
are additional cytosolic DNA sensors upstream of STING activated by self-DNA. 
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 TREX1 is the most abundant 3’ to 5’ exonuclease, and is localized to the 
endoplasmic reticulum (112, 121). It functions to digest DNA that has been 
reverse transcribed from endogenous retroelements, which are present 
throughout the genome and are capable of driving the production of IFN if 
unprocessed (122). In TREX1 deficient cells, ssDNA accumulates and is 
recognized by cGAS, leading to activation of STING and aberrant production of 
IFN via IRF3 (122, 123). Mice deficient for TREX1 are viable, but succumb to 
IFN-driven inflammatory disease postweaning, with a median survival of less 
than 6 months (122, 124). Cause of death is typically cardiomyopathy leading to 
circulatory failure (124), but knockout mice also present with increased 
macrophage activation and neural inflammation (125, 126). Furthermore, 
mutations in TREX1 have been implicated in human disease. Discovered in 1984, 
Aicardi-Goutières syndrome (AGS) is a rare inflammatory disorder that most 
commonly affects the brain and skin, causing encephalopathy and ultimately 
brain atrophy (127-129). The disease is driven by extremely high levels of IFN in 
the cerebrospinal fluid in the absence of infection (130, 131). Subsequent work 
revealed that mutations in any of seven genes causes AGS: the three genes 
encoding the RNase H2 endonuclease complex (132), the deoxynucleoside 
triphosphate triphosphohydrolase SAMHD1 (133), the dsRNA deaminase 
ADAR1 (134), the cytosolic dsRNA receptor MDA5 (135), and TREX1 (136). 
Notably, these enzymes are all involved in the processing or sensing of nucleic 
acids, implicating the accumulation of self-nucleic acids in the IFN-driven 
pathogenesis of AGS. 
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 Additionally, a separate mutation in TREX1 has been shown to drive the 
development of familial chilblain lupus erythematosus (CHLE) (137). CHLE is a 
poorly understood form of lupus wherein lesions are triggered by exposure to 
cold and/or damp climates, typically distributed symmetrically in the extremities 
(138). These patients also often develop antibodies against Sjögren’s-syndrome-
related antigen A (SSA), commonly referred to as anti-SSA/Ro (139). Anti-
SSA/Ro antibodies recognize nuclear antigens and are one of the most 
prominent specificities of autoantibodies in sporadic SLE (140), and have been 
strongly implicated in the development of neonatal lupus and/or congenital heart 
defects in utero (141). More broadly, genome-wide association studies have 
revealed strong associations between TREX1 and sporadic disease severity, 
suggesting a potential contribution to the exacerbation of symptoms (142). 
However, although DNASE2 and TREX1 deficiencies lead to autoimmunity, 
these responses are driven by aberrant interferon production rather than loss of 
tolerance to DNA and are thus distinct from classical SLE. Nevertheless, these 
findings emphasize the importance of self-DNA processing in the prevention of 
autoimmunity. 
 While DNASE2 and TREX1 both digest intracellular forms of self-DNA, 
DNASE1 is instead secreted extracellularly. DNASE1 was originally 
characterized in the context of pancreatic exocrine function, as it is released 
extensively into the digestive tract in addition to being present in circulation (143). 
Given the importance of TLR signaling in the pathogenesis of lupus which is 
suggestive of an extracellular form of DNA being key, there was considerable 
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interest in investigating potential roles for DNASE1 in SLE. Initial reports 
suggested that DNASE1 knockout animals developed mild anti-DNA and ANA 
(144). However, the autoimmunity displayed by these mice was underwhelming 
compared to other models, and these results were never replicated. There were 
also tenuous links between DNASE1 and human disease; reports of minor 
reductions in DNASE1 activity (144) or DNASE1 mutations in small cohorts of 
SLE patients (145). However, these studies were subsequently expanded upon 
and it is now accepted that if a role for DNASE1 in promoting autoimmunity exists, 
it is at best a minor contributor (146, 147). In addition, clinical trials wherein 
DNASE1 was administered to lupus patients failed to demonstrate any 
therapeutic benefit whatsoever (148). 
 
Strong links between DNASE1L3 and multiple forms of SLE 
 However, DNASE1 is just one member of the DNASE1 family, which also 
includes DNASE1-like 1 (DNASE1L1), DNASE1L2, and DNASE1L3. All family 
members share very similar catalytic domains and depend on the presence of 
Ca2+ and Mg2+ (149). DNASE1L3 came to prominence when it was identified in a 
small cohort of consanguineous Saudi Arabian patients with an aggressive form 
of inherited SLE affecting children at extremely young ages characterized by very 
high titers of anti-DNA antibodies (150). Further study of these patients revealed 
that they had a frameshift mutation in DNASE1L3 that led to total loss of the 
enzyme’s function (150). A second study of similarly consanguineous patients in 
Turkey with hypocomplementemic urticarial vasculitis syndrome (HUVS) also 
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identified two separate inactivating mutations (one frameshift, one insertion 
leading to exon skipping) in DNASE1L3 (151). HUVS is a recurring urticaria 
characterized by glomerulonephritis and loss of complement components, in 
particular C1q (151). This seems to be driven by the development of high titers of 
anti-C1q autoantibodies, leading to C1q depletion (151). Indeed, anti-C1q 
antibodies have been extensively linked to the development of SLE, suggesting 
that complement plays a key role in the clearance of potentially immunogenic 
molecules from circulation (152-155). Consequently, HUVS is very strongly 
associated with SLE, as the majority of patients with HUVS progress to develop 
SLE at some point in life (151). Finally and most recently, an additional family of 
patients was identified that also presented with extremely aggressive, early onset 
disease in Italy (156). Featuring the same mutation as the Turkish family, one 
extensively-studied Italian patient first presented with HUVS before proceeding to 
extensive autoinflammatory disease, including SLE, polyarthritis, and intestinal 
vasculitis, all of which were largely resistant to treatment with anti-inflammatory 
therapeutics (156). Thus, these studies demonstrated that very rare cases where 
DNASE1L3 function is completely lost lead to extremely aggressive anti-DNA 
and anti-C1q responses, leading to rapid onset of SLE. 
 However, to date fewer than 10 patients lacking DNASE1L3 entirely have 
been identified. It was unclear whether DNASE1L3 was relevant to sporadic 
disease, as it had never been identified as having potential involvement in 
sporadic SLE by GWAS. Curiously, one locus linked to SLE by GWAS 
extensively is PXK (157, 158). PXK encodes for a kinase of unknown function, 
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and efforts to link PXK to SLE have yet to be conclusive. However, PXK is in very 
close proximity to DNASE1L3 on chromosome 3, and closer examination of this 
genetic region led to the association between SLE and PXK to be reassigned to 
a single nucleotide polymorphism (SNP) in DNASE1L3 (159, 160). This particular 
SNP results in an amino acid substitution wherein arginine is replaced by 
cysteine at position 206 of DNASE1L3, and studies have shown that this R206C 
DNASE1L3 is hypomorphic (161, 162).  Thus, reinterpretation of GWAS have 
now linked the function of DNASE1L3 with the development of sporadic SLE. 
 
Unique features of DNASE1L3 
 Given these results, we decided to look more closely at DNASE1L3, also 
known as DNASE. Like the other DNASE1 family members, it has the same 
critical active site residues, an essential disulfide bridge, a calcium-binding 
domain, and an N terminal signaling peptide (163, 164). Unlike DNASE1, 
however, which is bound and inhibited by glomerular actin (165), DNASE1L3 
lacks the residues that facilitate this interaction and is thus actin independent 
(163). In addition, DNASE1L3 contains a greater number of positively charged 
residues, resulting in a much more basic isoelectric point compared to DNASE1 
(9.5 vs 4.8) (164). Notably, efforts to enhance the activity of DNASE1 to improve 
therapeutic applications led researchers to replace residues at six positions with 
basic substitutes, resulting in a hyperactive DNASE1 (166). At four of these six 
positions DNASE1L3 already features basic residues, suggesting that it likely 
more potent than DNASE1. 
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 Another important difference is the C terminus of these enzymes. 
DNASE1L3 has a unique and highly basic domain at its C terminus that is very 
strongly conserved across species (167). One of the earliest described 
applications for DNASE1L3 was its ability to block liposomal transfection, a 
function not possessed by DNASE1 (167). This activity was dependent on the C 
terminal domain, as a truncated form of DNASE1L3 was able to process 
uncoated but not coated DNA (167). In addition, this domain is sufficient to confer 
this activity, as fusing it to the C terminus of DNASE1 allows for the resulting 
chimeric protein to block transfection (167). In addition to digesting liposome-
coated DNA, DNASE1L3 is also able to digest chromatin even in the absence of 
a helper protease, unlike DNASE1 (168, 169). This finding has led to suggestions 
that DNASE1L3 plays a role in nuclear fragmentation during apoptosis (170, 171) 
and necrosis (172). However, DNASE1L3 is secreted into the extracellular space 
and requires cleavage of its N-terminal signal peptide by the secretory pathway 
(164), pointing to a likely function for DNASE1L3 in processing extracellular DNA. 
In addition, DNASE1L3 is not upregulated in apoptotic cells (164), so any role 
during cell death may be a secondary function. 
  
Generation and characterization of Dnase1l3-deficient mice 
Given the strong links between DNASE1L3 and both inherited and 
sporadic SLE, our laboratory decided to investigate whether mice lacking 
DNASE1L3 would develop the disease. Essential coding exons of Dnase1l3 was 
targeted via gene-trapping, resulting in the introduction of a LacZ cassette in its 
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place (173). Dnase1l3LacZ/LacZ knockout (KO) mice were viable, fertile, and were 
born at Mendelian frequencies. Given that a major shortcoming of other lupus 
models was the reliance on a particular background, Dnase1l3 KO mice were 
crossed onto two common inbred strains, C57BL/6 (B6) and 129SvEv (129). In 
addition, mice on mixed and F1 backgrounds were analyzed. 
 All KO mice on both pure backgrounds and on mixed backgrounds 
developed ANA that stained HEp-2 cells perinuclearly, a pattern consistent with 
severe human SLE (173). Both male and female mice as young as 5 weeks of 
age presented with elevated levels of autoantibodies against both dsDNA and 
chromatin as measured by enzyme linked immunosorbent assay (ELISA) (173). 
Notably, there was no increase in total IgG in anti-RNA IgG at any time point 
tested (173), demonstrating that loss of DNASE1L3 causes loss of tolerance 
against DNA specifically rather than broad immune activation. The rapid and 
specific responses to dsDNA and chromatin in these animals thus strongly 
suggest endogenous genomic DNA represents the primary autoantigen. 
 Having observed loss of tolerance to self-DNA at very early ages in these 
knockout mice, our laboratory next wanted to determine whether they went on to 
develop other symptoms of SLE. As these mice aged, there was an expansion of 
the CD11c+ MHC class II- CD11b+ Ly-6C- inflammatory monocyte population 
(173), which have been described in other models as being key for clearance of 
immune complexes (174). KO mice also developed splenomegaly at 50 weeks of 
age, and within these spleens presented with spontaneous germinal center (GC) 
formation and a corresponding increase in GC B cells (173). All KO mice also 
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displayed overt kidney pathology by 50 weeks, with significantly higher IgG 
deposition in kidney glomeruli compared to WT mice (173). In addition, KO mice 
on the 129 background had additional kidney irregularities, presenting with 
extensive glomerulonephritis (173). These studies in the lab thus conclude that 
the initial loss of tolerance to self-DNA in KO mice precedes extensive immune 
activation, deposition of immune complexes, and glomerulonephritis, all 
hallmarks of sporadic SLE in humans. 
 
Acceleration of disease in Dnase1l3-deficient mice after treatment with IFN 
 Our laboratory was intrigued by the observation that despite extremely 
early anti-DNA responses, extensive immune activation was not present in KO 
mice until roughly 30 weeks of age. Previous studies have shown that artificially 
increasing the production of IFN can dramatically accelerate the development of 
SLE (175). To test whether this also applied to Dnase1l3-deficient animals, WT 
and KO mice at young ages were injected with an adenoviral vector encoding 
IFN-5. The efficacy of the vector was determined by both direct measurement of 
serum IFN and of the IFN-inducible marker Sca-1 (173). Notably, KO mice 
treated with IFN rapidly developed anti-dsDNA IgG, and in addition presented 
with novel anti-RNA IgG responses (173). In contrast to previous experiments 
using KO mice, animals that received IFN had expanded compartments of 
inflammatory monocytes and T cells one-week post-injection (173). Furthermore, 
roughly two thirds of KO mice who received IFN perished after 35 weeks (173). 
These studies from the lab thus conclude that increases in IFN expression 
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dramatically accelerate the immune activation observed in Dnase1l3-deficient 
animals, which is reflective of severe SLE in DNASE1L3-deficient human 
patients and sporadic patients where IFN is upregulated. 
 
Disease in Dnase1l3 KO animals is independent of STING but not MyD88 
 Previous studies of DNASE1L3 have led to suggestions that it processes 
intracellular DNA (170-172), in a manner similar to DNASE2 or TREX1 (90, 176). 
If this were the case, one would predict that autoreactivity in Dnase1l3-deficient 
animals would be dependent on STING, as is the case in DNASE2 and TREX1 
knockout animals. To test the potential involvement of STING in driving anti-DNA 
responses in our model, mice doubly deficient in STING and DNASE1L3 or 
MyD88 and DNASE1L3 were generated. Characterization of these double 
knockouts revealed that ablation of STING did not reduce the levels of ANA, anti-
dsDNA IgG, anti-dsDNA-specific antibody secreting cells (ASCs) as measured by 
ELISPOT, kidney deposition of IgG, or splenomegaly (173). In stark contrast, 
when MyD88 was deleted in Dnase1l3-deficient animals every parameter tested 
returned to WT levels (173). Because MyD88 is responsible for transducing 
signals through TLRs and the IL-1 receptor, these data strongly suggest that 
DNASE1L3 targets extracellular DNA, which is in keeping with its secreted 
nature. In addition, these results clearly distinguish loss of DNASE1L3 from other 
examples of DNASE deficiency, as the autoinflammation caused by loss of 
DNASE2 and TREX1 are both rescued by the additional loss of STING. 
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 Thus, these studies from the lab strongly suggest that Dnase1l3-deficient 
animals represent a novel model of SLE, wherein the initial loss of tolerance is 
against an extracellular form of genomic DNA. These mice then go on to develop 
overt disease much later in life, presenting with classical hallmarks of SLE: 
expansion of inflammatory monocytes, splenomegaly, increased germinal center 
reactions, and kidney IgG deposition resulting in overt glomerulonephritis. 
Furthermore, the dispensability of STING for disease demonstrates that 
DNASE1L3 functions differently than TREX1 or DNASE2 in that it is not 
processing intracellular DNA. My project has focused on addressing outstanding 
questions concerning the mechanism by which DNASE1L3 prevents 
autoimmunity. Chiefly, we have attempted to identify the form or forms of 
extracellular DNA processed by DNASE1L3, and also sought to understand the 
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Chapter 1 
Development of a functional assay to identify sources of DNASE1L3 
 
Evolutionary relationships between the DNASE1 family members 
 Because DNASE1L3 is more potent, actin-independent, and has the 
unique C terminal domain, we wanted to determine the evolutionary relationship 
between the various deoxyribonucleases. To wit, using software from 
www.phylogeny.fr (177, 178), we generated a phylogenetic tree using human 
and mouse DNASE1, DNASE1L1, DNASE1L2, DNASE1L3, DNASE2, and 
TREX1. Our analysis revealed that DNASE1L3 appears to have been the first 
DNASE1 family member that evolved from DNASE2 (Fig. 1). Indeed, DNASE1 
appears to have evolved significantly later in comparison, even after DNASE1L1, 
which potentially explains why it lacks some of the features of DNASE1L3. The 
very high degree of homology between human and mouse DNASEs is also 




Figure 1: Phylogenetic tree of human 
and mouse deoxyribonucleases. 
Branch length is proportional to the 
number of amino acid substitutions per 
site. Generated with one-click analysis 
from www.phylogeny.fr: alignment by 
MUSCLE, curation by Gblocks, tree 
construction by PhyML, visualization by 
TreeDyn. 
 
 - 27 - 
Technical challenges presented by DNASE1L3 
 Having observed the development of a lupus-like disease in mice deficient 
for Dnase1l3, we sought to explore the mechanism by which DNASE1L3 
contributes to the enforcement of tolerance against self-DNA. The first priority 
was to establish a means of tracking DNASE1L3. Given the secreted nature of 
DNASE1L3 (168), we anticipated assessment of DNASE1L3 to consist of 
conventional methods, such western blotting, intracellular staining and flow 
cytometry, and ELISA. Unfortunately, due to the extensive homology between 
DNASE1L3 and DNASE1 (163), we were unable to identify a commercially 
available antibody that functioned adequately in any of our experiments (data not 
shown). 
 We then decided to investigate the possibility of generating a custom 
antibody within the lab by immunizing our knockout animals. This approach 
presented additional problems surrounding protein purification, however. 
DNASE1L3 has a signal peptide at its N terminus (169), rendering a 
hexahistidine (His) tag ineffective (Fig. 2). Furthermore and as we later confirmed, 
the critical nature of the C terminal domain for the function of DNASE1L3 (167) 
suggested that a His tag at the end of this region would dramatically affect its 
stability and/or function. Lacking the tools to purify DNASE1L3 to the degree 
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 Instead, we sought to develop a functional assay that would allow us to 
track the activity of DNASE1L3. We opted to take advantage of the unique C 
terminal domain of the enzyme. It had previously been noted that unlike DNASE1, 
DNASE1L3 has the unique ability to block liposomally-mediated transfection 
(167). This activity depended on the presence of the C terminal domain, as 
truncated forms of DNASE1L3 lost the ability to digest liposomally coated DNA 
(167). Thus, since coated DNA is only able to be processed by DNASE1L3, we 
can use its digestion as a specific readout. 
 
qPCR as a functional readout for the activity of DNASE1L3 
 We initially attempted to assess digestion of coated DNA by gel 
electrophoresis, but were unable to do so due to the nullification of the negative 
charge of DNA upon coating with positively-charged liposomal transfection 
reagents such as N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium 
methyl-sulfate (DOTAP) or TransIT. Instead, we decided to use quantitative 
polymerase chain reaction (qPCR) to determine the extent to which DNA had 
been digested after incubation with enzyme. For each qPCR reaction, a standard 
curve was generated using serial dilutions of the target plasmid. Importantly, 2 
Figure 2: Representation of the key features of DNASE1L3. Asterisks denote vital catalytic 
residues; bracket denotes a disulfide bridge that is required for function. The N terminal signal 
pepdide is cleaved during secretion. 
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M of Mg2+ and Ca2+ were added to the reaction, since DNASE1L3 is dependent 
on these ions (169). Notably, this technique was extremely sensitive, as plasmid 
could be consistently detected at the femtogram level. Using the standard curve, 
the amount of DNA remaining after each digestion was extrapolated and the 
percent of input (i.e. 1 ng) was calculated (Fig. 3). 
 
 
DNASE1L3 is uniquely able to digest liposome-coated and nucleosomal 
DNA via its C terminus 
To test our assay, we generated recombinant DNASE1L3 or DNASE1 via 
transfection of HEK293 cells, followed by harvest of the supernatant. Importantly, 
we used KnockOut serum replacement from Thermo Fisher in lieu of using fetal 
bovine serum (FBS) in our cell cultures, as the latter contains abundant DNASE1 
and DNASE1L3. We noted that recombinantly-generated DNASE1L3 was able to 
digest coated plasmid, whereas DNASE1 or an empty vector control did not (Fig. 
4A). In contrast, both DNASE1 and DNASE1L3 digested naked DNA with similar 
efficiency. Furthermore, we generated a truncated form of DNASE1L3 lacking the 
Figure 3: Standard curve for 
detection of DNASE1L3 
activity by qPCR. Serial 
dilutions of template DNA 
were used to generate a 
standard curve. DNA 
remaining after digestion with 
various DNASE-containing 
supernatants or sera was 
assessed by qPCR and the 
standard used to calculate the 
percentage of DNA remaining. 
A unique standard curve was 
generated for each individual 
experiment. 
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positively charged C terminal domain, and noted that it also completely failed to 
process coated DNA, but was still able to digest uncoated DNA (Fig. 4A). 
 Encouraged by our ability to replicate previously published results with 
our assay, we next sought to test the mutated form of DNASE1L3 linked to 
sporadic lupus. The SNP rs35677470 is a nonsynonymous mutation of C686 to 
T686, and results in the substitution of a cysteine residue in place of an arginine 
at position 206 of DNASE1L3 (159, 160). Notably, this substitution results in the 
loss of a potentially crucial hydrogen bond (159). The R206C variant had 
previously been reported to be inactive (179), so we decided to generate this 
variant using site-directed mutagenesis to test its activity in our assay. We noted 
that although the R206C variant is not completely bereft of activity, it was roughly 
10 fold less active than wild type DNASE1L3 (Fig. 4A). Crucially, this reduced 
activity was observed in the digestion of both coated and uncoated DNA, 
suggesting that this variant is hypomorphic but can still target liposome-coated 
DNA. 
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Finally, we were intrigued by previous studies of DNASE1L3 where it was 
shown to digest nucleosomal DNA from isolated nuclei much more efficiently 
than DNASE1 (169). Furthermore, DNASE1L3 was demonstrated to digest 
chromatin independently of helper proteases, whereas DNASE1 required 
supplementary proteolysis (168). Additional findings hypothesized a role for 
DNASE1L3 in the processing of genomic DNA during cell death via both 
apoptosis (170) and necrosis (172). To test the efficacy of our DNASE1L3 
against chromatin, we designed qPCR primers specific for the endogenous 
Figure 4: The C terminal domain of DNASE1L3 allows its activity to be specifically 
tracked as it confers the ability to digest coated DNA. A. Digestion of native or liposome-
coated plasmid DNA by recombinant DNASEs as assessed by qPCR. Supernatants containing 
the indicated DNASE were incubated with uncoated or coated plasmid DNA for one hour at 
37oC, and the DNA remaining after digestion assessed by qPCR using GFP-specific primers. 
Data are expressed as a percentage of input DNA (means +/- SD of three independent 
experiments). B. Digestion of purified human genomic DNA (gDNA) or purified human 
nucleosomes (nDNA). DNASEs were incubated with the DNA substrates for 10 minutes at 37oC, 
and the DNA remaining was assessed by qPCR using primers specific for the human Alu 
genomic repeat. Data are expressed as a percentage of input DNA (means +/- SD of three 
independent experiments). 
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retroelement Alu, of which roughly 106 copies are present in all primate genomes. 
We then incubated recombinant DNASEs with commercially purchased human 
nucleosomes (EpiCypher) and again performed qPCR to assess the extent to 
which the DNA had been digested. We allowed the incubation to proceed for only 
10 minutes, since at longer timepoints DNASE1 was able to digest nucleosomal 
DNA (data not shown). Overall though, we noted that DNASE1L3 was much 
more efficient than DNASE1 at digesting nucleosomal DNA, and that this activity 
was dependent on the presence of the basic C terminal domain (Fig. 4B). In 
addition, the hypomorphic R206C variant was again roughly 10 fold less efficient 
in processing nucleosomal DNA (Fig. 4B). Notably, all recombinant DNASEs had 
comparable activity against control genomic DNA (Fig. 4B), suggesting that the 
activity of DNASE1L3 against nucleosomal DNA is a unique property and is not 
due to differences in its production or release as opposed to other DNASEs. 
 
Minor perturbations of the C terminus caused by mutations dramatically 
affect the activity of DNASE1L3 
 Having established a means of testing DNASE1L3 activity specifically, we 
once again decided to pursue the generation of a tagged form of the enzyme. 
Initially, we began by placing a His tag immediately behind the signal peptide at 
the N terminus (DNASE1L3 His-N). Although this variant could digest uncoated 
DNA normally, it was unable to process coated DNA (data not shown). As there 
is no crystal structure for DNASE1L3, we examined that of the well-characterized 
DNASE1 (149, 165). The tertiary structure of DNASE1 is such that the N 
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terminus and C terminus are placed in close proximity, and the high degree of 
homology between DNASE1L3 and DNASE1 (Fig. 5A) suggests that this is likely 
the case for DNASE1L3 as well. Additionally, the key residues forming the 
interface between DNASE1 and DNA are very closely replicated in DNASE1L3 
(Fig. 5B). Thus, it seems likely that our His tag disrupts the C terminal domain, 






 Given the challenges DNASE1L3 presented, we decided to collaborate 
with structural biologists in order to more thoroughly understand the enzyme and 
to understand the importance of the C terminus. Molecular modeling revealed 
that the C terminus of DNASE1L3 forms an extremely rigid alpha helical structure 
Figure 5: The catalytic domains of DNASE1 and DNASE1L3 share extensive homology. 
A. Global sequence alignment of bovine DNASE1 (PDB:2DNJ.a; top) and human DNASE1L3 
(UniprotQ:Q13609). Red boxes represent amino acids of DNASE1 that contact DNA and 
orange lines represent selected residues contacting DNA. B. 3D structure of the complex of 
DNASE1 with DNA. Selected residues contacting DNA are colored orange.  
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when isolated (Fig. 6A) and also in the context of the entire protein (Fig. 6B). To 
test the importance of positioning of the C terminus, we created versions of 
DNASE1L3 with a His tag immediately preceding the C terminal domain (His-
preCT) and at the C terminus itself (His-CT). Modeling of these variants revealed 
that although the alpha helical nature of the basic domain was preserved, the 
tertiary structure was affected in the case of the His-preCT variant and the 
domain was masked in the His-CT form. (Fig 6C). Indeed, analysis of the activity 
of the His-CT DNASE1L3 revealed that while digestion of naked DNA was 
preserved, it was unable to process coated DNA or nucleosomal DNA, 
suggesting that the C terminus must be exposed to function (Fig. 6D). In contrast, 
the His-preCT DNASE1L3 retained its activity against coated DNA but was 
deficient in digestion of nucleosomal DNA (Fig. 6D). Overall, this suggests two 
distinct roles for the C terminal domain: it both allows for the penetration of 
DNASE1L3 through liposomes and, likely, lipid bilayers, and also allows it to 
digest nucleosomal DNA. 
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Figure 6: Perturbations of the C terminal domain of DNASE1L3 dramatically affect its 
function. A. ab initio structure prediction of the C terminus of DNASE1L3 (aa 282-305). 
Shown is the 3D structure of the lowest energy conformation (left) and the energy spectrum of 
the folding simulation (right). Importantly, there is a roughly 5 kcal gap between the lowest 
energy conformation and the first non-helical conformation, strongly suggesting an extremely 
rigid helical structure. B. Homology model of DNASE1L3 based on PDB:2NDJ, with ab initio 
structure prediction of the C terminus. The rigid -helical conformation of the C-terminal 
domain is unperturbed in the context of the whole protein. C. Homology modeling of 
hexahistidine-tagged versions of DNASE1L3. Although the -helical conformation of the C 
terminus is not affected, it is shielded in the His-CT variant and its packing against the protein 
is altered in the His-preCT mutant. D. Digestion by His-tagged DNASE1L3 variants, as in 
Figures 7A and 7B. Data are presented as percentage of input digestion, and are means +/- 
SD of three independent experiments. 
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Dnase1l3-deficient mice are unable to process liposome-coated DNA 
 In addition to testing recombinant DNASE1L3, we wanted to validate our 
assay using our Dnase1l3-deficient animals. We began by isolating serum from 
wild type or knockout animals and assessing its capacity to digest coated or 
uncoated DNA. Indeed, although knockout mouse serum could readily process 
uncoated DNA, we observed a defect in the digestion of coated DNA (Fig. 7A). 
To further confirm this phenotype, either uncoated or coated plasmid DNA was 
injected intravenously into wild type or knockout mice, with serum being collected 
3 hours post-injection and assessed by qPCR using GFP-specific primers. Again, 
while both wild type and knockout animals cleared uncoated DNA, the knockout 
animals were unable to process DNA after liposome coating (Fig. 7B).  
 
Figure 7: Dnase1l3-deficient animals do not process liposome-coated DNA ex vivo or in 
vivo. A. Sera from Dnase1l3-deficient animals does not process coated plasmid DNA as 
assessed by qPCR. Although robust digestion of naked DNA was observed by sera of both WT 
and KO mice, loss of DNASE1L3 resulted in an inability to digest liposome-coated DNA. Data 
are presented as % of input DNA, displaying individual mice as well as the median value. B. 
Dnase1l3-deficient animals fail to process circulating liposome-coated plasmid DNA. WT or KO 
mice were injected intravenously with 1 g of native or liposome-coated plasmid DNA, then bled 
3 hours later. After isolation of serum, the presence of plasmid DNA was determined by qPCR 
for GFP. Individual mice are shown, with bars representing the median. 
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Circulating DNASE1L3 produced by hematopoietic cells prevents 
autoimmunity 
 In order to test whether circulating DNASE1L3 was produced by 
hematopoietic cells or a radioresistant cell type, we performed reciprocal bone 
marrow (BM) transfers between WT and KO mice. We then tracked DNASE1L3 
activity over time in these mice by making a slight modification to our qPCR 
assay in order to compare small changes in 
circulating DNASE1L3. Whereas previously the 
standard curve was generated using serial 
dilutions of DNA in order to assess the 
percentage of DNA digested, we now diluted 
wild type serum to different percentages and 
incubated it with the same amount of coated 
DNA as our test reactions for a shorter amount 
of time (10 minutes vs. 1 hour). This allows for 
smaller changes in the amount of DNASE1L3 to 
be resolved. Using this technique, we observed 
progressive loss of systemic DNASE1L3 in WT 
mice that received KO bone marrow, and progressive gain in KO mice that 
received WT bone marrow (Fig. 8). Intrigued at these results, we decided to set 
up an additional set of long-term chimeras, wherein WT or KO bone marrow was 
injected into lethally irradiated WT mice. Consistent with our previous results, we 
observed progressive loss of DNASE1L3 activity in mice receiving KO bone 
Figure 8: Active DNASE1L3 in 
circulation is produced by 
hematopoietic cells. Reciprocal 
bone marrow chimeras were set up 
and circulating DNASE1L3 activity 
tracked over time by qPCR. Data are 
expressed as percentage of WT 
activity and are shown as means +/- 
SD of 6-8 mice per group. 
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marrow (Fig. 9A). In the group receiving KO BM, circulating DNASE1L3 activity 
was lost by 40 weeks post-transfer, which coincided exactly with the 
development of anti-dsDNA auto-Ab (Fig. 9A). At the experimental endpoint, we 
observed that these mice had eventually developed the hallmark symptoms of 
SLE: ANA, kidney deposition of IgG, and glomerulonephritis (Fig. 9B-D). We 
conclude that autoreactivity to self-DNA inversely correlates with circulating 
DNASE1L3 produced by hematopoietic cells. 
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Figure 9: The production of autoantibodies in Dnase1l3-deficient mice is driven by 
hematopoietic cells. A-D: The development of autoantibodies in WT mice lethally irradiated 
and reconstituted with bone marrow from WT or KO mice. A. Recipient mice were 
simultaneously assessed for circulating DNASE1L3 activity (left panel) and for the presence of 
anti-dsDNA IgG by ELISA (right panel) post reconstitution. The left panel is presented as 
percentage of WT activity (means +/- SD of six animals per group). The right panel shows 
individual mice, with bars representing the median. B. ANA in the sera of recipient mice at the 
55 week experimental endpoint, as in Figure 3A. Images are representative of six animals per 
group. C. Deposition of IgG in the kidneys of recipient mice, as in Figure 4G. Kidney sections 
stained for the presence of IgG by immunofluorescence are shown (left panels, representative of 
six animals per group), as well as the percentage of glomeruli with IgG deposition (right panel, 
out of 40 glomeruli per kidney, individual mice plus bars representing median). D. Assessment 
of kidney pathology in recipient mice, as in Figure 4I. Kidney sections were stained by H&E and 
histopathology scores were generated by a blinded pathologist. Shown is the percentage of the 
kidney cortex affected by inflammation (left panel, individual mice and median) and the median 
cumulative score of glomerulonephritis (right panel, individual mice and median). 
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 In order to directly test the effects of circulating DNASE1L3 on the 
development of autoreactivity, we injected young Dnase1l3 deficient mice with an 
adenoviral vector encoding human DNASE1L3 (Ad-DNASE1L3). Adenoviral 
injection in vivo results in the transduction of hepatocytes, allowing for the 
production of protein for several weeks until cleared. Indeed, after four weeks we 
observed total restoration of WT levels of DNASE1L3 in the knockout mice 
injected with Ad-DNASE1L3 compared to a control adenovirus (Fig. 10A). 
Crucially, we observed a significant delay in the development of anti-dsDNA IgG 
in these mice compared to controls (Fig. 10B). Overall, these results suggest that 
circulating DNASE1L3 produced by hematopoietic cells prevents the 




Figure 10: Restoration of circulating DNASE1L3 into Dnase1l3-deficient animals delays 
the development of autoimmunity. Young 4-week-old Dnase1l3-deficient mice were injected 
with adenoviruses encoding human DNASE1L3 (Ad-DNASE1L3) or GFP (Ad-GFP). A. Serum 
DNASE1L3 activity after adenoviral administration at the indicated time points, along with age-
matched WT controls. Data are presented as percentage of WT activity, and individual 
animals are shown with bars as the median. B. Serum titers of anti-dsDNA IgG in the same 
mice as measured by ELISA. Data are shown as the median +/- the range of four (Ad-GFP or 
WT) and nine (Ad-DNASE1L3) animals per group. 
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Identifying the cellular sources of circulating DNASE1L3 
 We then wanted to understand which cell type was responsible for the 
production of DNASE1L3 in systemic circulation. Because our Dnase1l3-deficient 
animals were generated through the use of a gene trap insertion of a LacZ 
cassette, we were able to use the fluorogenic substrate fluorescein di-V-
galactoside (FDG) to quantify -galactosidase activity in cells expressing 
Dnase1l3 by flow cytometry. We found that Dnase1l3 expression is largely 
restricted to myeloid cells, in particular CD11c+ classical dendritic cells (cDCs) 
and, to a lesser extent, macrophages (Fig 11A). Additionally, while it seems to 
not be expressed broadly in lymphocytes, innate-like B cell populations such as 
marginal zone (MZB) and CD5+ B-1a cells do have low levels of Dnase1l3 (Fig. 
11A). Furthermore, this limited expression we observed was confirmed by 
previously published microarray data in both humans (Fig. 11B) (180) and mice 
(Fig. 11C) (181). In addition, we performed qPCR on sorted cell populations from 
primary mouse splenocytes, and consistent with these previous results we noted 
that classical DCs had the highest levels of Dnase1l3 expression (Fig. 11D). 
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Figure 11: DNASE1L3 is expressed primarily by dendritic cells and macrophages. A. Flow 
cytometry analysis of Dnase1l3 expression in immune cells. Splenocytes from Dnase1l3LacZ/LacZ 
KO or WT mice were stained for the presence of LacZ as a proxy for DNASE1L3 using the 
fluorogenic substrate FDG. Histograms of FDG in the indicated gated cell populations are 
shown. Data are representative of three independent experiments. B. The expression of 
DNASE1L3 in human tissues and cell types. The expression profile of DNASE1L3 (probe 
205554_s_at) in the Primary Cell Atlas microarray expression database as visualized in the 
BioGPS browser (biogps.org) is shown, with relevant cell types indicated. C. The expression of 
Dnase1l3 in murine immune cell populations. The expression profile of Dnase1l3 in the Immgen 
microarray expression database of key populations (top panel) and monocytes/macrophages 
(bottom panel) are shown. D. The expression of Dnase1l3 in sorted murine splenocyte 
populations, as determined by qRT-PCR. Relative expression levels in the indicated cell types 
are shown, normalized to Actb (mean +/- SD of triplicate PCR reactions). Data are 
representative of five experiments. 
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 We went on to utilize the alternative protocol to test DNASE1L3 activity in 
our mice lacking specific populations to understand the extent to which each 
population contributes to normal WT activity in circulation. In Rag1-deficient 
animals that lack all lymphocytes, circulating DNASE1L3 was not reduced 
compared to wild type controls, ruling out potential contributions from innate-like 
B cells (Fig. 12A). However, upon transient depletion of cDCs and intestinal 
macrophages via injection of diphtheria toxin (DTX) into CD11c-diphtheria toxin 
receptor (DTR) mice, systemic DNASE1L3 levels were reduced by more than 
75% (Fig. 12B). To rule out any effects of the transgene, we injected WT mice 
with chlodronate liposomes, depleting tissue macrophages and reducing cDC 
numbers. These mice lost roughly 50% of DNASE1L3 activity compared to mice 
injected with control liposomes (Fig. 12C). And finally, depletion of intestinal 
macrophages via a single injection of anti-macrophage colony stimulating factor 
1 receptor (anti-Csf1r) blocking antibody resulted in a loss of roughly 15% of 
systemic DNASE1L3 (Fig. 12D). 
 
 




 Overall, we have designed an assay allowing the tracking of systemic 
DNASE1L3 activity based on its unique C terminal domain and resultant ability to 
digest liposome-coated DNA. Our data emphasize the extent to which this C 
terminal domain is crucial for the enzyme’s full activity, as the function of 
DNASE1L3 is majorly impaired by small adjustments to the stability or angle of 
the alpha helix. Importantly, this C terminal domain appears to have two roles for 
DNASE1L3; it both allows for the penetration of lipid bilayers and also for the 
digestion of nucleosomal DNA. We hypothesize that the former activity may be 
Figure 12: DNASE1L3 in circulation is produced primarily by dendritic cells and 
macrophages. A. DNASE1L3 activity in the sera of Rag1-deficient mice (individual animals 
and median). B. DNASE1L3 activity in the sera of DC-depleted mice. Animals with Cre-
inducible diphtheria toxin receptor (DTR) with or without DC-specific Cre deletion (Cd11c-
Cre) were injected with diphtheria toxin (DTX) intraperitoneally every other day for 2 weeks, 
and their sera was analyzed for DNASE1L3 activity (individual animals and median). C. 
DNASE1L3 activity in the sera of WT animals treated with liposomes containing either PBS 
or chlodronate to facilitate macrophage depletion on the indicated days after treatment 
(individual animals and median). D. DNASE1L3 activity in the sera of WT animals 12 days 
after intraperitoneal injection of control IgG or anti-Csf1r blocking antibody (individual 
animals and median). 
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due to its extremely basic properties while the latter may be due to the very 
stable and rigid structure this domain adopts, though further experiments are 
necessary to confirm. 
Furthermore, while dendritic cells and macrophages have been previously 
described to play key roles in the maintenance of tolerance and prevention of 
autoimmunity (182, 183), our data suggest a novel mechanism by which this 
takes place: the secretion of a systemic enzyme that processes extracellular self-
DNA. Its affinity for both membrane-encapsulated DNA and for nucleosomal DNA 
suggest that it processes some form of extracellular chromatin, preventing the 
activation of autoreactive B cells. The inverse correlation between DNASE1L3 
levels and anti-dsDNA autoAb indicates that DNASE1L3 is constantly required 
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Chapter 2 
Microparticles as the physiological target of DNASE1L3 
 
Microparticles as potential targets of DNASE1L3 
 We next wanted to determine the physiological form of self-DNA targeted 
by DNASE1L3. Taking into account the known properties of DNASE1L3 and our 
initial results, we inferred several likely characteristics of its target. Firstly, the 
self-DNA would probably be extracellular in nature, given the secreted nature of 
DNASE1L3 and its detectable presence in systemic circulation. Also pointing to 
an extracellular antigen is the dispensability of the intracellular DNA sensor 
STING in driving autoimmunity in knockout animals and the subsequent lack of a 
pronounced interferon (IFN) signature. Secondly, this DNA must be more or less 
ubiquitous, due to the constant requirement for the presence of DNASE1L3 to 
prevent autoimmunity. Thirdly, given the efficiency with which DNASE1L3 
processes coated DNA and nucleosomal DNA, it is likely membrane associated 
and chromatin based. Given these parameters, we hypothesized that apoptotic 
microparticles might be a potential target of DNASE1L3. Although microparticles 
have been primarily investigated in the context of thrombosis (184, 185) and 
cancer (186, 187), recent work has linked them to autoimmune disorders such as 
systemic sclerosis (188), rheumatoid arthritis (189), and other rheumatic 
diseases such as vasculitis (190). 
 Also known as microvesicles, microparticles are released from cells during 
both cell death and activation (191). They are small, membrane-bound vesicles 
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that are known to contain a variety of cytoplasmic and nuclear cargo, including 
proteins, messenger RNAs, micro RNAs, and other signaling molecules (192). 
Consequently, microparticles have been implicated in intercellular crosstalk and 
regulation, both locally and systemically (190, 193, 194). Their biological 
functions include modulation of the immune system, regulation of coagulation, 
and transfer of signaling molecules (191, 195-198). Finally, on top of potential 
roles in disease pathogenesis, microparticles can be used as biomarkers, since 
they reflect the surface markers and intracellular contents of their parent cells 
(191, 199-202). In addition, microparticles arising from apoptotic cells display 
phosphatidylserine on their surfaces, allowing for the binding of annexin V (191). 
The extent to which microparticle DNA is reflective of or represents total DNA in 
human plasma, however, remains unclear (203, 204). 
 
Links between microparticles and disease 
 Several recent studies have linked microparticles to systemic lupus 
erythematosus (189, 205-210). A particularly interesting study showed that 
although lupus patients did not have an increase in the numbers of microparticles, 
microparticles isolated from their bloodstreams had higher levels of autoantibody 
coating compared to controls (205, 207). In addition, it was shown that 
microparticles can be bound by DNA-specific autoantibodies (210). Furthermore, 
it has been established that apoptotic cells incorporate genomic DNA into 
released microparticles (211). Finally, these microparticles have been shown to 
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expose chromatin on their surfaces (210, 212-214), thus representing a 
potentially novel source of self-DNA for DNA-reactive B cells. 
 Previous therapeutic efforts focused on microparticles were conducted 
using DNASE1, which upon its discovery was tenuously linked to SLE (144, 145, 
215). Although no role for DNASE1 could ever be conclusively demonstrated, we 
hypothesized that microparticles may instead represent a potentially novel target 
of DNASE1L3 for several reasons. They are released extracellularly into 
circulation and are stable enough to have systemic effects (193), are present 
normally in the plasma of both healthy subjects and patients with SLE (205, 207, 
216), and are loaded with chromatin incorporated into cell membranes (190, 210, 
211). Given that our previous results suggested that the natural substrate of 
DNASE1L3 was likely to be ubiquitously produced, present in the blood, and 
chromatin based and/or membrane encapsulated (see Chapter 1), microparticles 
thus met all criteria as a physiological target. To test the potential effects of 
DNASE1L3 on microparticle DNA, we began by inducing the release of 
microparticles from the Jurkat T cell leukemia line. 
 
Induction and isolation of microparticles 
Staurosporine (STS) is a molecule originally isolated from the bacterium 
Streptomyces staurosporeus (217). STS functions as a competitive inhibitor of 
ATP, as it binds with very high affinity to many protein kinases (218). Previous 
studies have shown that Jurkat cells readily release microparticles upon STS 
treatment (191). We sought to confirm these findings, and indeed observed rapid 
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release of microparticles by Jurkat cells treated with STS (Fig. 13A) 
accompanied by comprehensive apoptosis (Fig. 13B). To quantify microparticles, 
we employed a combination of rapid centrifugation and flow cytometry to 
determine purity (Fig. 13C). 
 
Figure 13: Treatment with staurosporine induces rapid cell death and microparticle 
release. A. Extensive production of microparticles from Jurkat cells after treatment with 
staurosporine. Jurkat cells were treated with 1 mM staurosporine (STS) for the indicated amount 
of time. Cultures were harvested and stained with Annexin V and propidium iodide (PI) to 
assess cell death. Cell death was accompanied by a concordant increase in microparticle 
release. B. Near total induction of apoptosis in Jurkat cells treated with staurosporine. Jurkat 
cells were stained with Annexin V and PI after treatment with DMSO control (top panels) or STS 
(bottom panels) for 24 hours. C. Preparation of microparticles yields significant enrichment. 
STS-treated Jurkat cell cultures were first centrifuged to pellet cells, and supernatants were then 
spun at high speeds to pellet microparticles. After resuspension in sterile PBS, microparticles 
are assessed for purity by flow cytometry. 
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DNASE1L3 is uniquely able to digest microparticle DNA 
In order to test the digestion of human microparticle DNA, we designed 
qPCR primers specific for the Alu retroelement. The Alu element is a primate-
specific short interspersed element (SINE) that comprises roughly 11% of the 
human genetic code (219). Because more than 106 copies are dispersed 
throughout the genome, PCR typing between adjacent copies has been widely 
used both in forensic science and in the study of population genetics (220). In 
lieu of using PCR to assess the distances between individual elements, we 
designed primers to amplify Alu itself, reasoning that its abundance and wide 
distribution meant it was likely to be incorporated into microparticles at a high 
level. 
We began by assessing the capacity of recombinantly generated DNASEs 
to digest microparticle DNA by qPCR. As hypothesized, DNASE1L3 proved to be 
extremely efficient at eliminating microparticle DNA (Fig. 14A). This was in stark 
contrast to empty vector controls as well as DNASE1 (Fig. 14A), in concordance 
with previous studies that demonstrated an inability of DNASE1 to digest 
microparticle DNA (221). Wanting to understand whether this activity required the 
C terminal basic domain of DNASE1L3, we also assessed the capacity of our 
truncated DNASE1L3 to digest microparticle DNA. Confirming the importance of 
the C terminus, this modified DNASE1L3 was completely deficient in its ability to 
process microparticle DNA (Fig. 14A). Finally, we also assessed the variant of 
DNASE1L3 associated with sporadic lupus, R206C. As with uncoated and 
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coated plasmid DNA, DNASE1L3-R206C was hypomorphic, processing 
microparticle DNA with roughly 10-fold reduced efficiency (Fig. 14A). 
One potential caveat was our reliance on microparticles produced from the 
Jurkat cell line, which after extensive culture may not be reflective of cellular 
behavior in physiological settings. We decided to validate our results using 
microparticles produced ex vivo from mouse splenocytes. Because STS induces 
apoptosis and microparticle release much more extensively in proliferating cells, 
we stimulated the splenocytes with phorbol 12-myristate 13-acetate (PMA) and 
ionomycin. These two compounds are widely used in combination to drive 
proliferation, cytokine production, and cell activation via activation of protein 
kinase C (PKC) (222, 223). After 72 hours of stimulation with PMA/ionomycin, 
cells were treated with STS to induce microparticle release and microparticles 
were harvested as previously described for Jurkat cells. 
In order to measure digestion of mouse DNA by qPCR, we designed 
primers specific for the B1 family of retroelements. B1 repetitive elements are 
SINEs analogous to Alu in humans, and are present in similar abundance in the 
mouse genome (224). Consequently, we could perform qPCR using these 
primers and previously isolated mouse DNA to generate a standard curve. After 
digestion with recombinant DNASEs, we observed that again only DNASE1L3 
was capable of digesting DNA from splenocyte microparticles (Fig. 14B and data 
not shown), suggesting that the activity of DNASE1L3 is not limited to 
microparticles produced from a particular type of cell. 
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Finally, we also wanted to assess whether the sera of Dnase1l3-deficient 
animals would be able to digest microparticle DNA, or if loss of DNASE1L3 
resulted in a comparable phenotype to that observed for liposome-coated DNA. 
Jurkat microparticles were isolated and incubated with sera from WT or 
Dnase1l3-deficient mice. qPCR for the remaining human DNA revealed that sera 
from KO animals was largely unable to process microparticle DNA, whereas sera 
from WT animals efficiently digested this substrate extensively (Fig. 14C). These 
data emphasize the importance of DNASE1L3 in the digestion of circulating 
microparticle DNA, as other serum DNASEs had minimal effect on microparticle 
chromatin. 
 
 In addition to our qPCR-based assay, we wanted to assess digestion of 
microparticle DNA by an alternative readout. We ultimately opted to utilize flow 
Figure 14: DNASE1L3 is 
uniquely able to process 
microparticle DNA. A. Digestion 
of Jurkat microparticle DNA by 
recombinant DNASEs, as 
measured by qPCR. Data 
presented as means +/- SD of 
three independent experiments. 
B. Digestion of mouse 
splenocyte MPs by recombinant 
DNASE1L3. Four independent 
experiments are shown. C. 
Digestion of Jurkat MP DNA by 
sera from WT or KO mice. 
Individual animals and median 
are shown. 
 
 - 53 - 
cytometry in conjunction with a DNA-specific fluorescent dye to assess DNA 
integrity. Previous studies had shown limited effectiveness of propidium iodide 
(PI) in staining microparticles (221), likely due to their intact membranes. As an 
alternative, we decided to use a membrane-permeable dye used primarily for 
cell-cycle analysis, Vybrant DyeCycle Green (VG; ThermoFisher). We found that 
this dye extensively stained microparticles produced from Jurkat cells at very low 
concentrations (1:200,000) (Fig. 15). When microparticles were treated with 
recombinant DNASE1L3, there was dramatically reduced VG staining compared 
to microparticles treated with empty vector controls (Fig. 15). In stark contrast, 
treatment with DNASE1 had minimal effect on the VG staining of microparticles 
(Fig. 15). We also assessed the digestion of microparticles produced from 
splenocytes by flow cytometry, and confirmed that DNASE1L3 but not DNASE1 
dramatically reduces VG staining (data not shown). 
 
 





The surface composition of microparticles is altered by DNASE1L3 
 We also wanted to test for the presence of high mobility group box protein 
1 (HMGB1). HMGB1 is a non-structural nuclear protein that is known to 
associate with nucleosomes, helping to facilitate transcription (225). However, 
HMGB1 also functions as a key proinflammatory cytokine extracellularly. Upon 
stimulation of macrophages with lipopolysaccharide (LPS), HMGB1 is released, 
which activates NF-B via TLR4 (226). In addition to being produced by activated 
cells, HMGB1 functions as an alarmin, as it is also commonly released during cell 
death (227). HMGB1 has been described to be released concomitantly with 
microparticles, and may indeed associate with them due to its affinity for 
Figure 15: A membrane permeable DNA 
dye extensively stains microparticles 
only in the absence of DNASE1L3. 
Jurkat microparticles were isolated and 
treated with recombinant DNASEs, then 
stained with Vybrant Green membrane 
permeable DNA dye at a dilution of 1 to 
200,000 for 20 minutes at room 
temperature. MPs were then analyzed on 
an Attune NxT flow cytometer. Data are 
representative of six independent 
experiments. 
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nucleosomal DNA (226-228). Furthermore, HMGB1 has been linked to the 
pathogenesis of SLE as both a proinflammatory signal that contributes to cell 
activation and as a potential target of autoantibody development (229-231). 
Consequently, we wanted to investigate whether DNASE1L3 was capable of 
reducing HMGB1 levels on microparticles through the processing of nucleosomal 
DNA using flow cytometry. Upon digestion of microparticle DNA by DNASE1L3, 
there was comprehensive loss of HMGB1 binding to their surfaces (Fig. 16A). 
Furthermore, we noted that HMGB1 staining was restricted to DNA-positive MPs 
as labeled by Vybrant green, and we further confirmed that DNASE1L3 has 
dramatic effects on microparticle DNA (Fig. 16B). We thus conclude that 
DNASE1L3 processes microparticle DNA in vitro, likely reducing their 
immunogenicity and surface composition. 
 
 
Figure 16: DNASE1L3 
treatment of microparticles 
alters their surface 
composition. A. Jurkat MPs 
were treated with rDNASEs 
and then stained for the 
presence of HMGB1. Mean 
fluorescence intensity is 
indicated. B. Costaining of 
pretreated Jurkat MPs with 
anti-HMGB1 and Vybrant 
green. Notably, there are 
very few HMGB1 single 
positive MPs, indicated 
strong associations between 
HMGB1 and MP DNA. 
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Loss of DNASE1L3 results in a failure to process endogenous circulating 
microparticles in vivo 
 We next sought to assess potential changes to endogenous microparticles 
present in DNASE1L3 knockout animals. Previous work in the lab had examined 
circulating DNA in the sera of knockout versus wild type mice using the 
fluorescent DNA-intercalating dye PicoGreen. We had observed no differences in 
DNA in the sera between wild type and knockout animals (Fig. 17A). In light of 
our findings regarding microparticles, however, we decided to return to these 
experiments. Importantly, the process by which sera is collected from mice 
involves extended centrifugation at 22,000 x g, meaning that our serum samples 
were likely free of microparticles. Furthermore, during serum collection the 
coagulation process is allowed to proceed, which could result in the release of 
DNA not normally present in steady state circulation. 
 Thus, in lieu of sera, we decided to isolate plasma using less rapid 
centrifugation. In order to collect plasma, we required an anticoagulating 
substance. Because we intended to perform qPCR on our isolates, we could not 
use the most common anticoagulant, ethylenediaminetetraacetic acid (EDTA). 
Instead, we used commercially purchased heparin to isolate plasma from WT 
and Dnase1l3-deficient animals. When whole plasma was assessed by qPCR, 
we could now observe a significant difference between DNA present in the 
plasma of wild type and knockout animals (Fig. 17B). 
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 We then wanted to assess the endogenous microparticles of these mice 
more specifically. To that end, we isolated plasma as above, and after isolation 
spun the plasma at 22,000 x g for 30 minutes to pellet microparticles. These 
were then resuspended and stained with anti-CD41 and anti-Ter119, which are 
specific for platelets and red blood cells, respectively. This was necessary 
because platelets and debris from erythrocytes are approximately the same size 
as microparticles and are also pelleted by these centrifugation steps. The 
negative fraction was then counted on an Accuri tabletop flow cytometer in order 
to precisely determine the numbers of relevant apoptotic microparticles (Fig. 
18A). Notably, although microparticle count varied considerably from mouse to 
mouse, we observed no difference between wild type and knockout animals (Fig. 
18B). We then performed qPCR using B1-specific primers on this material and in 
conjunction with the flow cytometry data calculated the amount of DNA per 
microparticle. We noted that microparticles isolated from knockout animals 
contained on average four orders of magnitude more DNA compared to those 
from wild type animals (Fig. 18C). To further show the specificity of the defect to 
Figure 17: Dnase1l3-deficient 
mice have higher levels of DNA 
circulating in plasma. A. No 
difference in the amount of DNA in 
the sera of WT and KO mice, as 
determined by staining with the 
DNA intercalator PicoGreen. 
Individual mice and median are 
shown. B. qPCR on whole murine 
plasma from WT or KO animals 
using primers specific for the B1 
genomic repeat. Individual mice 
and median are shown. 
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microparticle DNA, we also performed qPCR on the non-microparticle fraction of 
plasma (i.e. the supernatant after the rapid spin to pellet microparticles). We 
noted that there was virtually no DNA present in plasma outside of microparticles, 
and indeed were unable to detect DNA reliably despite our qPCR amplifying 
standards at the femtogram level (data not shown). 
 
 
Finally, we also decided to inject exogenous microparticles generated 
from Jurkat cells into wild type and knockout animals to assess their ability to 
cope with a sudden burden of microparticle DNA. 6 x 106 Jurkat microparticles 
were injected intravenously into 6 wild type and 6 knockout animals, and the 
mice were then bled 3 hours later. After isolation of plasma, qPCR using Alu-
specific primers was then performed. We again observed a defect in knockout 
Figure 18: Microparticles from 
Dnase1l3-deficient mice carry 
increased amounts of DNA 
compared to those of WT mice. A. 
Identification of the relevant MP 
fraction from the plasma of mice. 
Only events within the MP gate that 
were negative for CD41 and Ter119 
were counted as bona fide MPs. No 
differences between WT and KO 
mice were observed. Representative 
of nine mice per group. B. No 
difference in the total numbers of 
MPs isolated from WT or KO mice 
was observed. Individual animals 
and median are shown. C. Increased 
DNA in MPs isolated from KO mice 
compared to WTs. qPCR was 
performed on isolated MPs using B1 
primers, and the total amount of DNA 
in the reaction was then divided by 
the number of MPs included. 
Individual mice and median are 
shown. 
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animals in the processing of exogenous microparticles, noting a significant 
increase in microparticle DNA equivalents per L of plasma (Fig. 19). Knockout 
animals were hugely deficient in clearing microparticle DNA, as they made little 
impact on overall amounts for 24 hours (data not shown). We thus conclude that 




 These data suggest that DNASE1L3 is responsible for the processing of 
nucleosomal DNA contained within circulating microparticles. Our initial results in 
Dnase1l3-deficient animals suggested that its endogenous substrate was likely to 
be nucleosomal and/or membrane associated in nature. Microparticles represent 
an underappreciated source of extracellular genomic DNA (192, 202, 211, 221), 
and by definition have intact plasma membranes (221). Because chromatin is 
potentially immunogenic, its persistence in circulation on microparticles may 
compromise tolerance to self-DNA. DNASE1L3 rapidly processes the DNA load 
of microparticles, as we have demonstrated by two independent readouts. 
Figure 19: Dnase1l3-deficient 
mice fail to process exogenous 
microparticles in vivo. 6 x 106 
Jurkat microparticles were injected 
intravenously into WT or KO mice, 
and plasma samples taken 3 hours 
post administration. qPCR for 
human Alu repeats was then 
performed. Individual mice and 
median are shown. 
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Furthermore, treatment of microparticles with DNASE1L3 reduces the binding of 
HMGB1 to their surfaces, which represents a potent proinflammatory molecule 
that has been extensively linked to the pathogenesis of SLE (225, 229-232). This 
finding thus demonstrates that DNASE1L3 can fundamentally affect the profile of 
circulating microparticles even beyond their DNA content. 
 The sheer scale of granulocyte turnover alone (>109 per kg per day) (233) 
ensures that microparticles are ubiquitously present throughout circulation at the 
steady state. Thus, the previously observed requirement for the presence of 
DNASE1L3 in order to prevent the development of anti-dsDNA autoreactivity is in 
keeping with the context of continuous microparticle release. Indeed, a recent 
paper that focused on deep sequencing of cell-free DNA from human plasma 
found that the majority is hematopoietic in origin, with an especially large amount 
coming from granulocytes (203). We believe that the vast majority of DNA 
analyzed by these authors originated from microparticles, since they used whole 
plasma and because we found virtually no DNA in the microparticle-free plasma 
fraction in mice. 
 Overall our results indicate that microparticles represent a novel source of 
antigenic self-DNA, in particular in the absence of DNASE1L3 where it is allowed 
to persist in circulation for extended periods of time. DNASE1L3 is uniquely 
capable of processing microparticle DNA due to its basic C terminal domain. 
DNASE1 in contrast had minimal impact on microparticle DNA, confirming 
previous studies (191) and again emphasizing the importance of DNASE1L3 as 
opposed to DNASE1 in circulation. Importantly, our data demonstrate that there 
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is no defect in microparticle release or production, but rather that produced 
microparticles are not rendered immunologically benign in circulation. 
Additionally, the production of microparticles as a consequence of cell death may 
be relevant for human disease, which typically features flares that can be 
triggered by a huge variety of stimuli, including but not limited to exposure to UV 
radiation, viral infection, pregnancy, and physical injury (1, 12, 234-236). Even in 
individuals with no defect in DNASE1L3, overwhelming the system with a large 
quantity of DNA-loaded microparticles may allow for increased persistence and 
the opportunity for microparticles to trigger anti-DNA autoimmunity. 
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Chapter 3 
Microparticles as autoantigens 
 
Roles for microparticles in human disease 
 Having established that microparticles are not processed fully in the 
absence of DNASE1L3, we next wanted to assess their potential as antigen-
loaded targets of autoimmune responses. While the rapid development of 
autoantibodies against dsDNA and, in particular, chromatin in our knockout 
animals suggest a loss of tolerance to these molecules that may be caused by 
their increased presence in microparticles, we sought to determine whether 
microparticles themselves represent suitable B cell antigens. Understanding 
whether microparticle-driven autoimmunity is based on direct interaction with B 
cells is potentially key for further elucidation of the mechanisms underlying 
pathogenesis. Importantly, DNA may behave as an unconventional antigen due 
to its ability to stimulate the production of cytokines via TLR activation in addition 
to its intrinsic immunological properties. 
 Numerous studies have offered potential explanations for the systemic 
effects attributed to microparticles, including but not limited to priming of dendritic 
cell and neutrophil subsets (216), metalloprotease and cytokine production by 
fibroblasts (196), induction of soluble selectin release (188), crosslinking of 
receptors on endothelial cells (198), interactions with galectin-3 binding protein 
(206), activation of interferon production by plasmacytoid DCs (237), and direct 
delivery of cytokines or other signaling molecules (185, 193, 208). Alternatively, 
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microparticles have been proposed to be targets of autoantibodies, directly 
contributing to the formation of immune complexes in rheumatic diseases such 
as SLE (192, 205, 207, 209, 210, 214, 238). Furthermore, other mouse models of 
SLE, including the MRL-lpr/lpr spontaneous lymphoproliferative mutants as well 
as the NZB/NZW F1 generation present with anti-microparticle autoantibodies 
(209, 214). Given the rapid development of anti-dsDNA and anti-chromatin 
autoantibodies in our mice and the strong association between anti-DNA 
autoantibodies and disease severity in lupus patients (56, 74, 83, 89), we wanted 
to investigate the potential binding of autoantibodies to microparticles and the 
effects of DNASE1L3 on the repertoire of antigens present on microparticle 
surfaces. 
 
Microparticles are bound by circulating IgG from Dnase1l3-deficint animals 
 We began by investigating the extent to which microparticles were bound 
by autoreactive antibodies from Dnase1l3-deficient mice compared to controls 
using flow cytometry. Microparticles isolated from Jurkat cells were incubated 
with sera from wild type or knockout mice, followed by a fluorescent secondary 
antibody. We observed dramatically increased binding of the sera of knockout 
animals compared to that of controls to microparticles (Fig. 20A), suggesting that 
microparticles represent viable B cell autoantigens. In addition, we tested sera 
from mice at different ages to establish whether binding to microparticles 
worsened during lupus pathogenesis. Strikingly, we observed clear increases in 
microparticle binding over time in knockout mice but not in wild type animals (Fig. 
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20B), indicating that microparticles are indeed bound by pathogenic 
autoantibodies that increase in prevalence over time and correlate with disease 
severity in Dnase1l3-deficient mice. 
 We next wanted to investigate the potential effects of treatment with 
DNASE1L3 on autoantibody binding to microparticles. To this end, we treated 
Jurkat microparticles with an empty vector control, recombinant DNASE1, or 
recombinant DNASE1L3. From there, we stained each group of microparticles 
with the sera from five different knockout mice at 20 weeks of age. While 
DNASE1 had minimal effects on the binding of mouse sera to autoantibodies 
compared to the empty vector control, treatment with DNASE1L3 completely 
ablated all binding (Fig. 20C). Overall these results demonstrate that 
microparticles represent viable B cell antigens, and that treatment of 
microparticles with DNASE1L3 dramatically reduces their immunogenicity. 
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Circulating microparticles from knockout animals are coated with IgG 
 Next, we investigated the coating of endogenous circulating microparticles 
by antibodies in wild type or knockout mice. As previously, we exsanguinated 
young mice at 10 weeks of age into heparin in order to isolate plasma. We found 
Figure 20: DNASE1L3-sensitive chromatin on the surface of microparticles is antigenic in 
Dnase1l3-deficient mice. A-C: Binding of circulating murine IgG to the surface of human 
apoptotic microparticles. Jurkat MPs were incubated with sera from Dnase1l3 KO or control WT 
animals, followed by secondary anti-mouse IgG fluorescent antibody. A. Representative 
histograms of mouse IgG fluorescence on the surface of Jurkat MPs. Percentage of positive 
MPs is indicated. B. Percentage of mouse IgG positive Jurkat MPs bound by WT or KO mice at 
the indicated time points. Data are presented as median +/- range of five animals per group. C. 
Jurkat microparticles were incubated with supernatants containing recombinant human 
DNASE1L3, DNASE1, or an empty vector control prior to staining with serum from Dnase1l3-
deficient animals. Representative histograms are shown in the left panel, with the percentage of 
IgG positive MPs indicated. The right panel shows individual mice, with the bars representing 
the median. 
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that even at 10 weeks of age, knockout animals had more extensive binding of 
IgG to endogenous microparticle surfaces (Fig. 21A). Additionally, we stained 
these endogenous microparticles with PR1-3, a monoclonal antibody specific for 
anti-DNA/histone 2a/2b complexes (210). We noted significantly higher levels of 
PR1-3 binding to microparticles isolated from knockout mice compared to those 
from wild type mice (Fig. 21B), suggesting that in addition to being more coated, 
endogenous microparticles in young Dnase1l3-deficient animals have higher 





Figure 21: Microparticles from 
Dnase1l3-deficient mice at 
young ages are more coated by 
IgG and have higher levels of 
exposed self-antigens. A. 
Staining of MPs isolated from 
mouse plasma from WT and KO 
mice for mouse IgG. The left panel 
shows representative histograms 
with the MFI indicated, and the 
right shows MFIs of individual mice 
with bars representing the median. 
B. MPs isolated from young WT or 
KO mice were stained using the 
anti-DNA/histone antibody PR1-3. 
Representative histograms are 
shown in the left panel with the 
percentage of PR1-3 positive MPs 
indicated, and the right shows 
percentage of PR1-3 positive MPs 
from individual mice with bars 
representing the median. 
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Microparticles drive loss of tolerance to self-DNA in inflamed conditions 
 To further examine the ability of microparticles to drive anti-nucleic acid 
autoimmunity, we decided to inject them into mice and assess the subsequent 
autoantibody levels. Our initial experiments used microparticles isolated from 
Jurkat cells, but unfortunately these elicited massive germinal center and 
inflammatory responses in all settings. In retrospect, this is unsurprising due to 
the fact that Jurkat cells constitutively release murine gammaretroviruses picked 
up during extensive passaging in culture (239) in addition to the presence of 
potent cross-species and anti-tumor host responses. Thus, we instead opted to 
produce syngeneic microparticles from mouse splenocytes treated with PMA and 
ionomycin, as previously (see Chapter 2). In order to assess de novo anti-DNA 
autoimmunity, we could not use Dnase1l3-deficient animals, as they have 
autoantibodies from extremely early ages. Instead, we injected wild type mice 
with an adenovirus encoding IFN-5, delivery of which has been shown to 
accelerate the development of SLE in experimental models (175) as well as in 
Dnase1l3-deficient mice (173). These mice rapidly presented elevated levels of 
both IFN and the IFN-inducible gene Sca-1, confirming adenoviral efficacy (data 
not shown). Microparticle injections into these mice but not naïve mice produced 
very high titers of anti-nucleosome IgG (Fig. 22). These data demonstrate that 
MPs can function as antigens that elicit chromatin-specific B cell autoimmunity in 
the context of elevated interferon. 
 
 




DNASE1L3-sensitive chromatin on microparticles is accessible to 
autoantibodies 
 We next wanted to establish whether microparticles were bound by a 
variety of anti-chromatin monoclonal antibodies, and whether this binding was 
affected by treatment of microparticles with DNASE1L3. To this end, we obtained 
four hybridomas from our collaborator Dr. Mark Shlomchik that produce 
antibodies specific for different DNA/histone complexes implicated in SLE: PR1-3 
(DNA/histone 2a/2b), PR2-8 (DNA/histone 2a/2b, DNA/histone 3/4), PR9-11 
(naked DNA), and 29A-3H9 (isolated from 3H9 transgenic mouse that presents 
with very high anti-dsDNA and anti-ssDNA). 
 To test binding of these anti-chromatin antibodies and the potential effects 
of DNASE1L3, Jurkat microparticles were treated with recombinant DNASEs 
Figure 22: Immunization with 
microparticles drives anti-
chromatin antibody responses 
in inflammatory contexts. WT 
mice were administered IFN5 
adenovirus (IFN), MPs from 
syngeneic apoptotic splenocytes 
(MP), or both. Serum titers of anti-
nucleosome IgG was measured 
one week post final injection by 
ELISA. Titers from individual 
animals and the median are 
shown. 
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prior to staining with our hybridoma antibodies. We noted that all antibodies 
bound to microparticles treated with the empty vector control extensively, further 
confirming that microparticles represent viable antigens for anti-chromatin B cell 
responses (Fig. 23). Furthermore, treatment with DNASE1 had a minimal impact 
on autoantibody binding (Fig. 23). In contrast, treatment with DNASE1L3 
significantly reducing binding of all autoantibodies, providing further evidence that 
DNASE1L3 is key for modulating the immunogenicity of microparticles, limiting 






Figure 23: Treatment of microparticles with DNASE1L3 but not DNASE1 prevents binding 
by DNA-specific autoantibodies. Microparticles isolated from Jurkat cells were treated with 
supernatants containing recombinant DNASE1, DNASE1L3, or an empty vector control. They 
were then stained with murine antibodies against DNA and/or chromatin originally isolated from 
mouse SLE models, followed by a fluorescent anti-mouse secondary. Shown are representative 
histograms from four experiments, with the percent of IgG positive MPs indicated. 
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The C terminus of DNASE1L3 is required to prevent autoantibody binding 
to microparticles 
 We also wanted to test the extent to which the C terminus of DNASE1L3 
is required for this activity, as well as the extent to which the DNASE1L3-R206C 
hypomorphic form retains its function. To that end, we again isolated Jurkat 
microparticles, and treated them with a vector control, DNASE1, DNASE1L3, 
truncated DNASE1L3, or DNASE1L3-R206C. From there, we stained these 
treated microparticles with purified PR1-3, which was provided by our 
collaborator Dr. Keith Elkon. Washing and staining with our secondary antibody 
was unchanged from previous experiments. Strikingly, we observed that 
truncated DNASE1L3 had a minimal effect on PR1-3 binding to microparticles, in 
stark contrast to wild type DNASE1L3 (Fig. 24A). In contrast, DNASE1L3-R206C 
was capable of preventing PR1-3 binding to similar levels, but given that our 
previous qPCR experiments suggested that it still retained considerable activity 
this was not unanticipated (Fig. 24A). We also went on to test the activity of our 
self-generated His-tagged DNASE1L3 variants. Although we had previously seen 
that the his-preCT variant, which has a his tag immediately preceding the C 
terminal -helix retained its activity against coated DNA. When tested for its 
ability to process microparticle DNA, however, we found that this variant was 
unable to reduce binding of PR1-3 (Fig. 24B). The his-CT variant of DNASE1L3, 
which has a His tag at the end of the C terminus, was previously unable to 
process coated DNA and was similarly deficient here (Fig. 24B). These data 
demonstrate that in the absence of DNASE1L3, microparticles are extensively 
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bound by anti-chromatin autoantibodies and that incubation of microparticles with 
DNASE1L3 is sufficient to render them non-immunogenic. In addition, the spatial 
integrity of the C terminal domain is vital for this function of DNASE1L3, as even 
slight perturbations of the enzyme’s tertiary structure can dramatically impact its 




Microparticles are bound by prototypical autoantibodies from human SLE 
 Finally, we wanted to assess the relevance of microparticles in human 
disease. Human antibodies that are positive for the 9G4 idiotype are greatly 
Figure 24: The C terminal domain of DNASE1L3 is required for the processing of 
microparticle chromatin. A. Microparticles from Jurkat cells were incubated with recombinant 
DNASEs and subsequently stained with the purified anti-nucleosome antibody PR1-3 followed 
by a fluorescent secondary antibody. Histograms are shown with the percentage of IgG positive 
MPs indicated. Data are representative of three experiments. B. As in A, Jurkat MPs were 
treated with the indicated mutant forms of DNASE1L3 and then stained with PR1-3. Histograms 
are shown with the percentage of IgG positive MPs indicated. Data are representative of three 
experiments. 
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enriched among SLE-associated autoantibody repertoires (240, 241). They have 
been shown to bind to a variety of antigens, including DNA, nuclear components, 
and apoptotic cell nuclei (240, 241). We obtained a panel of 22 chimeric 
antibodies consisting of Fab fragments isolated from patients fused with the 
mouse IgG Fc region from our collaborator, Dr. Iñaki Sanz. We wanted to assess 
binding of these antibodies to Jurkat microparticles that had been treated with an 
empty vector or with DNASE1L3 by flow cytometry, as we had done previously. 
Given the minimal effects we had observed of DNASE1 on antibody binding and 
the limited quantities of primary antibody available, we elected to omit it from our 
analysis. We observed three different binding patterns: some antibodies did not 
bind to MPs at all, some bound to all MPs, and some bound to MPs treated with 
the vector control only (Fig. 25A). Of our panel of 22 antibodies, 9 bound to 
microparticles treated with the vector control, and of these, 6 then failed to bind 
to microparticles after DNASE1L3 treatment (Fig. 25B). These DNASE1L3-
sensitive antibodies were reactive against apoptotic cell membranes, and were 
positive for anti-nuclear antigen staining (241). These findings suggest that 
microparticles may represent novel sources of antigen in sporadic SLE in 
addition to rare cases where there is DNASE1L3 deficiency. 
 
 





 Overall these results demonstrate that microparticles represent sources of 
self-antigen that are accessible to B cells. Furthermore, data from our knockout 
mice suggest that antibody responses to microparticles are enhanced over time, 
indicating that they play a role in disease pathogenesis. Additional evidence for 
this stems from the observation of increased coating of IgG of endogenous 
microparticles from knockout animals compared to wild type controls. On top of 
that, our experiments injecting microparticles into permissive mice show that they 
also likely play a role in the loss of tolerance observed in SLE. We hypothesize 
that failure to process microparticle DNA represents the primary insult driving the 
development of anti-dsDNA autoimmunity in Dnase1l3-deficient mice. 
 Identifying the specific form or forms of DNA recognized by B cells during 
the pathogenesis of SLE remains a major challenge of the field. While multiple 
Figure 25: A subset of 
human 9G4+ antibodies bind 
to microparticles only in the 
absence of DNASE1L3. A. 
Jurkat MPs were treated with 
an empty vector control or with 
DNASE1L3, and were then 
incubated with 9G4+ mAbs. 
Three patterns were observed: 
no binding to any MPs, binding 
to all MPs, and binding to MPs 
treated with vector control only. 
Representative histograms of 
each group are shown from left 
to right, respectively. Data are 
reflective of three independent 
experiments. MFIs of IgG 
bound to MPs are indicated. B. 
Classification of the 22 
different 9G4+ clones tested 
based on binding pattern. 
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types of DNA have been linked to the pathogenesis of SLE, including neutrophil 
extracellular traps, self-DNA complexed with anti-microbial peptides, and 
oxidized mitochondrial DNA (104-107, 242), their potential as B cell antigens 
remains unresolved. In contrast, our results demonstrate that microparticles 
enriched in genomic DNA in the absence of DNASE1L3 are extensively bound by 
autoreactive antibodies, many of which have been implicated in the pathogenesis 
of SLE (210, 214, 240, 241). Furthermore, the reductions in autoantibody binding 
observed specifically after treatment of microparticles with DNASE1L3 but not 
DNASE1 indicate a fundamental role for DNASE1L3 in preventing the 
development of autoimmunity. 
 Importantly, our data emphasize that the defect in DNASE1L3-deficient 
animals stems from a failure to process microparticles rather than an issue in 
their production. After digestion with DNASE1L3, microparticles appear to be 
rendered inert with respect to anti-DNA and anti-chromatin immune responses, 
though the presence of additional autoantigens on their surface is also likely as 
evidenced by the binding of three 9G4+ antibodies to DNASE1L3-treated 
microparticles. Furthermore, our results using 9G4+ antibodies indicate a 
potential role for microparticles in sporadic lupus. Although it seems unlikely that 
there may be overt defects in microparticle DNA processing at the steady state, 
microparticles may represent novel sources of self-antigen in sporadic patients. 
Finally, given the widespread links between cell death and/or stress and the 
pathogenesis of SLE (235, 236), the resulting temporary increase in microparticle 
burden may contribute to disease and/or flare onset. 
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 Overall we believe our Dnase1l3-deficient mouse represents a novel, 
comprehensive, monogenic model of SLE. This lupus is driven by a failure to 
process the DNA contained within apoptotic microparticles in circulation, which 
are normally produced primarily from granulocytes. Chromatin-containing 
microparticles function as potent self-antigens for autoreactive B cells, and the 
unique properties of DNASE1L3 allow it to process this chromatin and render 
microparticles to be nonimmunogenic. Finally, we believe that our model 
describes a novel cell-extrinsic mechanism of self-tolerance to DNA mediated by 
DCs and macrophages that may allow for therapeutic intervention. 
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Chapter 4 
DNASE1L3 and microparticles in human lupus patients 
 
Circulating cell-free DNA in humans is contained within microparticles 
  Given our comprehensive studies of Dnase1l3-deficient mice, our findings 
that a subset of 9G4+ antibodies are reactive against microparticles in a 
DNASE1L3-sensitive manner, and the DNASE1L3-sensitive nature of 
microparticle chromatin, we believed that microparticles may represent 
unappreciated sources of antigen in human disease. In particular, recent work 
has suggested that loss of tolerance in human SLE is initially to chromatin, with 
subsequent epitope spreading to DNA specifically and other nuclear 
autoantigens (152, 243). Furthermore, it is increasingly accepted among the field 
that DNA-specific autoantibodies are among the most pathogenic variants, and 
their prevalence has been strongly linked to poorer outcomes for patients (56, 74, 
83, 89). Because DNASE1L3 is able to dramatically reduce the efficiency with 
which DNA and chromatin-specific antibodies bind to microparticles in other 
contexts, we wanted to directly investigate human patients.  
 Thanks to a collaboration with the Department of Rheumatology at NYU 
and Dr. Jill P. Buyon and Dr. Robert M. Clancy, we were able to obtain samples 
from a large cohort of patients with SLE. We were initially interested in assessing 
the surface markers present on microparticles to determine the cells from which 
they are primarily derived. These studies were far more feasible to perform in 
human settings compared to mice simply due to the major differences in 
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obtainable plasma volume. A recent study of cell-free DNA in human circulation 
focused on deep sequencing as a means of determining nucleosome positioning 
and, hence, cell type of origin (203). They concluded that the vast majority of cell-
free DNA comes from hematopoietic cells, with a particularly large amount 
stemming from granulocytes (203). This was in line with a previous study where 
the authors examined a cohort of patients that received sex-mismatched bone 
marrow transplants, then examined cell-free DNA (244). They noted that the 
DNA present in plasma was predominantly of donor origin, demonstrating that 
hematopoietic cells contribute the majority of cell-free DNA (244). 
 
Circulating microparticles in humans are primarily of hematopoietic origin 
We performed flow cytometry on microparticles isolated from human 
plasma, and observed positive staining of CD45 and CD66 on Annexin V positive 
microparticles, confirming that circulating microparticles originate largely from 
granulocytes (Fig. 26A). In addition, we wanted to determine the extent to which 
microparticle DNA comprises total plasma cell-free DNA. To assess this, after 
rapid plasma centrifugation of human samples, qPCR was run in parallel 
between the pelleted microparticles, the remaining soluble fraction, and 
unfractionated plasma. We found that there was virtually no DNA present in the 
non-microparticle fraction of plasma, and correspondingly microparticle DNA 
made up nearly all detectable DNA in total plasma (Fig. 26B). We thus conclude 
that microparticles released from granulocytes and other hematopoietic cells 
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make up the bulk of circulating DNA, and therefore are likely an important source 





Mutations in DNASE1L3 result in defective digestion of coated and 
nucleosomal DNA in humans 
Via our collaboration with Drs. Buyon and Clancy, we were extremely 
fortunate to obtain plasma samples from DNASE1L3-deficient human patients 
previously characterized with hypocomplementemic urticarial vasculitis syndrome 
(HUVS) (151). Patient 1 had presented with SLE in addition to HUVS but is now 
in remission, while patient 2 presented with HUVS only. Thus, neither patient was 
affected by active SLE at the time of blood sampling, ruling out potential 
Figure 26: Analysis of 
human microparticles. A. 
Phenotype of circulating 
microparticles in human 
plasma. MPs were isolated 
and stained for CD42b and 
CD235a to eliminate platelets 
and RBCs. We defined MPs as 
being FSClo SSClo CD42bneg 
CD235aneg. Representative 
stainings are shown comparing 
Annexin V versus the 
endothelial marker CD31, the 
leukocyte marker CD45, and 
the granulocyte marker 
CD66b. B. Distribution of 
human genomic DNA between 
the microparticle fraction and 
the soluble fraction of human 
plasma. DNA was measured 
by qPCR in unfractioned 
plasma, MPs, and the soluble 
fraction. DNA amounts per L 
of the original unfractioned 
volume are shown in samples 
from SLE patients (n=8) or 
healthy controls (n=2). 
 
 - 79 - 
secondary effects of the disease. We also obtained blood samples from their 
haplodeficient parents, neither of whom ever manifested with effects of SLE nor 
HUVS (151). 
 We began by assessing the activity of DNASE1L3 in the plasma of these 
patients. Using the digestion of liposome-coated plasmid DNA, we confirmed the 
total lack of DNASE1L3 activity in the plasma of these patients, while their 
haplodeficient parents had roughly 50% activity (Fig. 27A). In addition, we 
analyzed 3 patients who were heterozygous for the hypomorphic R206C variant 
of DNASE1L3, and observed that these patients had roughly 60% of DNASE1L3 
activity (Fig. 27A), indicating that this variant is approximately 5 fold less active 
than the wild-type form in vivo. 
 In addition, we assessed the extent to which patient plasma could digest 
commercially-purchased nucleosomal DNA over short incubations, as we 
previously showed in mice (see Chapter 1). As in Dnase1l3-deficient mice, 
DNASE1L3-null human patients were totally unable to process human 
nucleosomal DNA compared to normal controls (Fig. 27B). Additionally, while the 
haplodeficient parents could digest nucleosomes to a greater extent than the 
patients, they were also broadly deficient compared to controls (Fig. 27B). Finally, 
we determined whether null and haplodeficient patients were capable of 
processing microparticle DNA. We induced and isolated microparticles from 
Jurkat cells, then incubated them with plasma from these null patients. As with 
digestion of nucleosomal DNA, null patients were greatly deficient in their 
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capacity to digest microparticle DNA, while the haplodeficient parents were 
partially deficient (Fig. 27C). 
 
 
Patients lacking DNASE1L3 present with increased microparticle DNA  
 Having confirmed that these patients were indeed deficient for DNASE1L3 
and that our assay developed in mice could be applied to these rare human 
patients, we wanted to analyze the DNA content of circulating microparticles ex 
vivo. As we were working with human plasma, we utilized the same protocol 
optimized in mice in order to pellet microparticles from plasma. These pellets 
Figure 27: DNASE1L3 null mutations in human patients result in defective DNA 
processing that parallels Dnase1l3-deficient mice. A-C. Plasma from 2 DNASE1L3-
deficient patients, their haplodeficient parents, individuals with the hypomorphic R206C 
polymorphism (n=3), and normal control subjects (n=2-5) were analyzed. A. DNASE1L3 
activity in patient plasma, measured by qPCR of DOTAP-coated plasmid DNA after 
incubation. Data are expressed as a percentage of the activity in reference control plasma. 
Individual human subjects and median are shown. B. Digestion of human nucleosomal DNA 
by human plasma. Data are expressed as a percentage of the input DNA. Individual human 
subjects and median are shown. C. Digestion of chromatin in microparticles by the soluble 
fraction of patient plasma. Individual subjects and median are shown. 
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were resuspended and stained with anti-CD42b and anti-CD235a in order to 
eliminate platelets and erythrocyte debris respectively, which are commonly 
included after microparticle isolation due to their similar size. The stained 
microparticles were then assessed by flow cytometry, and the negative fraction 
counted precisely. In parallel, qPCR on these isolated microparticles was 
performed along with a human DNA standard curve, and, in conjunction with the 
precise quantification of starting material as determined by flow cytometry, the 
mass of DNA contained in each microparticle was calculated. Because platelets 
and erythrocytes do not contain DNA, we were unconcerned about potential false 
reads stemming from their inclusion in the qPCR reaction. Strikingly, we found 
that DNASE1L3-null patients had hugely elevated levels of DNA per microparticle 
compared to controls, with haplodeficient parents again at intermediate levels 
(Fig. 28A). Additionally, we assessed three patients heterozygous for the R206C 
hypomorphic variant and found that they also had elevated levels of DNA in 
circulating microparticles (Fig. 28A). 
 As we previously showed that microparticle DNA represents the vast 
majority of circulating DNA in human plasma, we also assessed the levels of 
DNA in unfractionated plasma from these patients by qPCR. Indeed, we 
observed increased DNA in total plasma of DNASE1L3-null patients compared to 
controls, with haplodeficient parents and R206C heterozygous patients 
intermediate (Fig. 28B). Collectively, we believe that these genetic data in both 
mice and humans demonstrate that DNASE1L3 is required for normal digestion 
of DNA in plasma, in particular in microparticle DNA. 
 
 - 82 - 
 
 
DNASE1L3-sensitive binding of patient IgG to microparticles 
 We next wanted to assess the extent of autoreactivity against 
microparticles in these null patients. To do this, we employed the same protocol 
used previously in Dnase1l3-deficient mice. Briefly, microparticles were isolated 
from Jurkat cells, then treated with an empty vector control or with recombinant 
DNASE1L3. After incubation these microparticles were stained with plasma from 
patients, then washed and stained again with an anti-human IgG secondary 
antibody. Flow cytometry was employed to determine the extent of binding. We 
found that only plasma from the patient who had previously developed SLE 
contained microparticle-specific autoantibodies (Fig 29). Notably, this binding 
was completely absent when microparticles were treated with DNASE1L3 (Fig. 
29). The patient who did not develop full blown SLE and the healthy 
haplodeficient parents did not have microparticle-specific autoantibodies (Fig. 29). 
It is also notable that the first patient retains detectable levels of these 
Figure 28: DNASE1L3 null 
mutations in humans result 
in defective processing of 
endogenous microparticles 
in circulation. A. The amount 
of genomic DNA in MPs 
isolated from patient plasma. 
Results are shown as the 
amount of DNA per MP as 
determined by qPCR. 
Individual subjects and median 
values are shown. B. The 
amount of genomic DNA per 
volume of total unfractionated 
patient plasma, as determined 
by qPCR. Individual subjects 
and median values are shown. 
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autoantibodies despite being in disease remission after treatment with rituximab, 
a potent therapeutic antibody that blocks B cell activation. Given the very high 
levels of DNA in the microparticles of both patients and the lack of an immune 
response in the second patient, these data strongly suggest that accumulation of 




Binding of circulating IgG from sporadic SLE patients to microparticles 
 While studies of these DNASE1L3-null patients provide compelling genetic 
evidence validating many of our experiments using mice, the applicability of our 
findings to the much more prevalent sporadic disease remain unclear. 
Furthermore, the rarity of patients that fully lack DNASE1L3 make detailed 
analysis unfeasible. Consequently, we sought to determine whether these 
findings were of relevance to SLE more generally. To accomplish this, we again 
Figure 29: DNASE1L3-sensitive binding of patient IgG to exogenous microparticles. 
Jurkat microparticles were treated with an empty vector control or with DNASE1L3, then 
incubated with plasma from human subjects followed by a secondary anti-human IgG 
fluorescent antibody. Histograms from DNASE1L3 haplodeficient parents are shown as well as 
the fully deficient patients. Percentage of IgG positive MPs is indicated for each condition. 
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took advantage of our collaboration with Drs. Buyon and Clancy of the NYU 
Department of Rheumatology, obtaining plasma samples from 136 patients with 
SLE and 12 controls. We began by assessing the prevalence of anti-
microparticle autoantibodies in all patients and controls, again using 
microparticles isolated from Jurkat cells that were treated with a vector control or 
with DNASE1L3. 
We observed major variability in the extent to which both treated and 
untreated microparticles were bound by patient plasma. We began by examining 
binding to untreated microparticles. As expected, there was a very strong 
correlation between the percentage of microparticles bound by IgG and the mean 
fluorescence intensity of stained microparticles (R2=0.82) (Fig. 30). We decided 
to define patients as being positive for anti-microparticle IgG if we observed 
binding to at least 5% of microparticles, calling them “Binders”. The roughly 20% 
of patients that failed to meet this threshold (28/136) we deemed to be “Non-
binders” (Fig. 30). Notably, none of the control plasma tested bound more than 
5% of microparticles (Fig. 30). Patients with anti-microparticle antibodies bound 
to 30.59 +/- 16.50% of control treated microparticles (Fig. 30). 
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We then compared the binding of each patient to microparticles treated 
with DNASE1L3, and noted that patients fell into three classifications: one group 
bound to microparticles only in the absence of DNASE1L3 (DNASE1L3-
sensitive); one group bound to microparticles regardless of DNASE1L3 treatment 
(DNASE1L3-insensitive); and one group failed to bind to microparticles 
regardless of treatment (non-binder) (Fig. 31A). To mathematically categorize 



























Binders Non binders Controls
Figure 30: Extensive binding of microparticles by the plasma of patients with 
sporadic SLE. Microparticles from Jurkat cells were stained with the soluble fraction of 
patient plasma, followed by a fluorescent anti-human secondary antibody. Shown is the MFI 
of IgG fluorescence versus the percentage of positively stained microparticles for each 
human subject. Positive binding was defined as > 5% IgG positive MPs (blue circles). 
Patients who bound to fewer than 5% were classified as non-binders (red circles). Healthy 
control subjects all failed to bind (green circles). 
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percentages of microparticles bound and the total mean fluorescence intensity 
(MFI) between incubation with native or DNASE1L3-treated microparticles. 
Patients were considered insensitive to DNASE1L3 treatment if there were no 
changes of at least 2 fold in either percent of microparticles bound or in MFI. Our 
calculations showed that 35.3% of patients bound to microparticles in a 
DNASE1L3-sensitive manner (48/136), while 44.1% (60/136) bound regardless 
of treatment with DNASE1L3 (Fig. 31B). These data demonstrate that 
microparticles represent an important source of B cell self-antigens in sporadic 
SLE and that treatment of microparticles with DNASE1L3 is sufficient to 
modulate their immunogenicity in some patients. 
 
Figure 31: Classification of 
sporadic SLE patients 
based on DNASE1L3 
sensitivity of IgG binding. 
A. Patient plasma was used 
to stain MPs treated with an 
empty vector control or with 
DNASE1L3. Representative 
histograms of IgG staining 
for each reactivity pattern are 
shown. Percentages of IgG 
positive MPs are indicated. 
B. The distribution of 
sporadic SLE patients into 
categories based on their 
staining pattern (n=136).  
 
 - 87 - 
DNASE1L3 activity varies between sporadic patients 
 We also wanted to assess the activity of circulating DNASE1L3 in these 
patients. To do this, we employed the same assay we had developed to look at 
depletion mouse models (see Chapter 1). In brief, different amounts of wild type 
serum were titrated and used to digest 1 ng of coated plasmid DNA in order to 
determine a standard. Digestion with patient plasma could thus be calculated as 
a percentage of normal activity. We began by assessing the activity of controls 
versus SLE patients, noting a much greater range of activity levels across 
patients (Fig. 32A). However, when we separated patients by their categorized 
binding to microparticles, we noted that patients that bound to microparticles in a 
DNASE1L3-sensitive manner had significantly lower levels of DNASE1L3 activity 
compared to controls, non-binding patients, and DNASE1L3-insensitive binding 
patients (Fig. 32B). Because DNASE1L3 is an extracellular protein whose activity 
in circulation is key to protect against the development of autoimmunity, this 
cohort may be the most amenable to therapeutic intervention via the delivery of 
DNASE1L3. Further investigation is required to determine whether the decline in 
DNASE1L3 activity in these patients is potentially contributing to loss of tolerance 
or if it is a secondary effect due to ongoing disease. In addition, understanding 
exactly what is causing these differences could yield valuable insights into the 
regulation of DNASE1L3 both in inflamed conditions and at the steady state. 
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 Finally, we wanted to assess whether the variability we observed in 
DNASE1L3 activity was reflected in differences in endogenous microparticle 
DNA in patients. We isolated microparticles from human plasma by centrifugation, 
then counted microparticles by flow cytometry as previously, again only 
considering the fraction negative for the platelet and erythrocyte markers CD41b 
and CD235a. Due to limitations of detection, we only considered patients from 
whom we were able to isolate at least 1000 microparticles, leaving us with 36 
Figure 32: The activity of 
DNASE1L3 in the circulation 
of sporadic SLE patients 
differs according to the 
observed pattern of staining. 
A. DNASE1L3 activity assays 
of all sporadic patients and 
healthy controls, as measured 
by the digestion of DOTAP-
coated plasmid DNA, 
expressed as a percentage of 
the activity in reference control 
plasma. Individual subjects 
and median are shown. B. 
DNASE1L3 activity assays of 
SLE patients only, classified 
based on their previously 
determined pattern of binding 
to native and DNASE1L3-
treated MPs. Individual 
subjects and median are 
shown. 
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patients. We performed qPCR using Alu-specific primers to quantify the amount 
of DNA present in each sample, then divided by the number of microparticles 
used in the test to yield DNA per microparticle. Notably, there was a strong 
inverse correlation (R2=0.492) between circulating DNASE1L3 activity and DNA 
per microparticle in sporadic patients (Fig. 33). These data suggest that even 
small changes in DNASE1L3 activity can impact the amount of DNA present in 





 Overall these data demonstrate that chromatin on the surface of 
circulating apoptotic microparticles represents an antigen for autoreactive B cells 
and immune complexes in sporadic and inherited human SLE. In patients lacking 
active DNASE1L3, we observed strikingly higher levels of DNA in circulating 
microparticles, confirming our studies using Dnase1l3-deficient mice. 
Furthermore, the presence of high levels of microparticle DNA in the absence of 
Figure 33: Changes in 
DNASE1L3 activity in 
sporadic patients 
impacts the DNA cargo 
of microparticles. DNA 
load of MPs isolated 
from the plasma of 
sporadic patients was 
determined by qPCR 
and flow cytometry. The 
soluble fraction was 
used to assess 
DNASE1L3 activity. 
Individual patients and 
best fit line are shown. 
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active SLE in the second patient indicate that this elevation may be the primary 
defect that leads to loss of tolerance upon interaction of autoreactive B cells with 
DNA-laden microparticles. Also intriguing is the consistent observation of anti-
C1q autoimmunity in DNASE1L3-deficient patients; further studies are required 
to determine the potential links between microparticles and complement. One 
possibility is that increased chromatin in microparticles due to loss of DNASE1L3 
results in C1q binding with greater avidity, as previous studies have 
demonstrated that DNA is a substrate for C1q (153, 245, 246). This increased 
binding could lead to enhanced clearance of C1q and also potential activation of 
autoreactive clones, resulting in the high levels of anti-C1q autoantibodies 
observed in these patients and ultimately HUVS (151). 
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Discussion and Future Directions 
 
Dnase1l3-deficient mice represent a novel, monogenic model for the study 
of inherited SLE 
 Loss of DNASE1L3 in humans results in extremely aggressive, early onset 
SLE driven by anti-dsDNA IgG that lacks a sex bias (150, 151). Upon knockout of 
Dnase1l3 in mice, we observed the same features on two independent pure 
strains as well as on mixed backgrounds: loss of tolerance to self-DNA leading to 
elevated titers of anti-DNA and anti-chromatin antibodies at very early ages, 
followed by late-onset immune activation driven by immune complex deposition. 
Importantly, this model provides the means to study inherited SLE in mice; 
previous efforts have been unsuccessful. As previously discussed, defects in the 
complement component C1Q have been tied to severe SLE, and in fact null 
mutations in C1Q cause SLE in human patients (90, 176). In mice, however, 
C1Q is dispensable, as its knockdown fails to cause any discernable pathology 
(247). Consequently, to our knowledge Dnase1l3-deficient mice represent the 
only mouse model of hereditary SLE reflective of human disease. In addition, 
these data provide an explanation for the extensive conservation observed 
between mouse and human DNASE1L3. 
 An outstanding question regarding this model concerns the delayed 
immune activation observed, which is in contrast to other mouse models and to 
DNASE1L3-deficient patients. The rapid development of autoreactivity against 
dsDNA and chromatin only led to comprehensive immune activation in old 
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animals, and furthermore these mice failed to lose tolerance to other self-
antigens (e.g. RNA). One possible explanation for this is the lack of 
supplementary mutations prominent in other mouse models. For instance, the 
Yaa mouse features enhanced sensing of RNA due to duplication of TLR7, while 
the Faslpr model is driven by aberrant lymphoproliferation and defective negative 
selection. Another important consideration is the lack of baseline immune 
stimulation in mice housed under specific pathogen-free conditions compared to 
human patients, especially considering the extensive literature linking viral 
infections and the resulting antiviral immune responses to SLE flaring in patients 
(4, 24, 84). Strong evidence for this hypothesis stems from our observation that 
artificially introducing IFN into Dnase1l3-deficient animals dramatically 
accelerated autoimmunity and induced novel anti-RNA responses, and 
furthermore led to substantial mortality. Further studies could similarly take 
advantage of this model to examine the effects of other triggers linked to flares in 
human disease. In particular, induction of apoptosis in vivo by pharmaceutical 
means may yield insights into environmental effects on pathogenesis in humans. 
We thus conclude that anti-DNA reactivity directed against chromatin in these 
mice causes the observed pathologies, and furthermore primes for severe SLE-
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Autoimmunity in Dnase1l3-deficient mice is distinct from that seen in 
Dnase2- or Trex1-deficient animals 
 Previous studies of DNASE1L3 pointed towards a potential role in the 
processing of intracellular DNA molecules, in particular during apoptosis or 
necrosis (170-172). However, cytoplasmic sensing of DNA requires the 
intracellular adaptor molecule STING, as evidenced by the ablation of disease 
when STING is deleted in conjunction with either DNASE2 or TREX1 (126, 248). 
Disease in Dnase1l3-deficient animals, in contrast, was totally independent of 
STING, suggesting that DNASE1L3 processes an extracellular form of DNA. In 
addition, our lab observed that disease was completely dependent on MyD88, 
which may point to a role for TLR or IL-1 signaling. Importantly, aberrant 
activation or any developmental defects in either DCs or B cells in very young 
Dnase1l3-deficient animals was not detected. We therefore hypothesize that the 
observed primary response to DNA may be driven by direct recognition by and 
subsequent expansion of DNA-reactive B cells, in all probability by extrafollicular 
activation. These primary signals are then amplified by a MyD88-dependent 
pathway or pathways in B cells or possibly other cell types. Thus, a critical future 
direction remains identifying the specific MyD88-dependent signals involved, 
which would provide additional insight into the mechanisms underlying loss of 
tolerance to genomic DNA which drives autoimmunity in Dnase1l3-deficient 
animals. More broadly, the extrafollicular production of autoantibodies may be a 
unique property of self-DNA as an antigen, as it has recently been shown that 
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activation of TLR7 or TLR9 in conjunction with BCR signaling results in robust 
affinity maturation in the absence of germinal centers (249). 
 
The presence of DNASE1L3 in circulation is required constitutively to 
prevent the development of anti-dsDNA autoimmunity 
 We observed that the levels of DNASE1L3 inversely correlated with the 
development of anti-dsDNA Abs. This suggests that the presence of DNASE1L3 
is constitutively required in circulation in order to prevent interactions between 
extracellular DNA and autoreactive B cells. We also demonstrate that the 
majority of serum DNASE1L3 is produced by DCs and subsets of tissue 
macrophages, in concordance with previously published microarray data. In 
particular, CD11c+ DCs produced roughly 70-75% of circulating DNASE1L3. 
While DCs and macrophages have been previously shown to play key roles in 
mediating self-tolerance and thus preventing autoimmunity (182, 183), we 
believe our data present a novel mechanism by which this occurs. While it is 
established that phagocytosis of apoptotic cells, induction of tolerogenic T cell 
programs, and the production of anti-inflammatory molecules and cytokines are 
all means by which self-tolerance is maintained by DCs and macrophages, here 
we demonstrate that the release of a DNA-digesting enzyme into circulation is 
required to prevent the activation of autoreactive B cells. 
 One confounding observation we made concerned the kinetics of 
DNASE1L3 activity after hematopoietic reconstitution. In wild-type mice receiving 
Dnase1l3-deficient bone marrow, activity persisted in these animals until roughly 
 
 - 95 - 
30 weeks, despite typical splenic dendritic cell turnover being on the order of 
days (250). This may be due to the production of DNASE1L3 into circulation in 
response to lethal irradiation by a non-hematopoietic radio-resistant cell 
population such as hepatocytes, which normally express DNASE1L3 although 
they seemingly do not contribute to circulating levels at the steady state. 
Alternatively, long-lived resident macrophage populations may persist and 
upregulate DNASE1L3 in response to the inflammation induced by total body 
irradiation, allowing for some degree of compensation. Further studies examining 
potential contributions of hepatocytes or tissue resident cells to systemic 
DNASE1L3 under duress may provide context for these findings. 
 
Microparticles are an endogenous substrate of DNASE1L3 
 The unique features of DNASE1L3 described here and by others led us to 
hypothesize that its endogenous substrate is chromatin-loaded circulating 
microparticles, for several reasons. Firstly, the requirement for DNASE1L3 
systemically in order to prevent autoimmunity indicates that its substrate must be 
present in circulation ubiquitously. Microparticles containing DNA are present 
normally in circulation (205, 216) as a consequence of the constant and rapid 
turnover of various blood cell types, in particular granulocytes. Secondly, 
DNASE1L3 is uniquely able to digest membrane-encapsulated DNA. This activity 
is dependent on its highly basic C terminus, the importance of which is made 
clear by the unusual degree to which it is conserved evolutionarily. Microparticles 
are intact structures that sequester DNA, as evidenced from the requirement to 
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disrupt microparticle membrane integrity with detergents in order to robustly stain 
with propidium iodide. Thirdly, the efficiency with which DNASE1L3 digests DNA 
packaged into nucleosomes suggests its target is likely chromatin-based. 
Microparticles contain the vast majority of detectable genomic DNA in human 
plasma, which is comprised of primarily nucleosomal chromatin fragments 
derived from leukocytes (203, 204, 251). Consequently, mice deficient for 
Dnase1l3 had significantly higher levels of DNA within their circulating 
microparticles as well as in their total plasma, which was corroborated in both 
DNASE1L3-deficient human patients and their haplodeficient parents. Thus, 
although it is possible that DNASE1L3 may process other types of self-DNA, our 
data demonstrate that genomic DNA contained within microparticles is a relevant 
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Microparticles are relevant sources of B cell antigens 
 Previous studies have also shown that chromatin on circulating 
microparticles is exposed and can be bound by autoantibodies (210, 212, 213), 
demonstrating that microparticle DNA represents a viable antigen for B cells. 
DNASE1L3 digests this exposed chromatin on microparticles, preventing the 
binding of autoantibodies from Dnase1l3-deficient animals and from the 
DNASE1L3-deficient patient who had previously developed SLE. In addition, our 
Figure 34: Proposed mechanism by which DNASE1L3 prevents the development of 
autoimmunity. As microparticles are released from cells undergoing constant turnover, 
DNASE1L3 released into circulation by dendritic cells and macrophages digests their 
chromatin contents. This prevents interactions between DNA-specific B cells and this 
antigenic self-DNA, ultimately resulting in tolerance to self-DNA. In the absence of 
DNASE1L3, chromatin-loaded microparticles persist in circulation and are able to be 
presented to DNA-specific T cells, ultimately resulting in the activation of autoreactive B cells 
and the release of anti-dsDNA antibodies. 
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experiments using murine hybridomas and 9G4+ monoclonals demonstrate that 
this chromatin is recognized by numerous archetypal autoantibodies found in 
both mouse and human SLE in a DNASE1L3-sensitive manner. Finally and most 
broadly, we observed binding by IgG from roughly 40% of sporadic patients to 
DNASE1L3-sensitive chromatin on microparticles. Endogenous microparticles 
from lupus patients have been previously described to be extensively bound by 
complement and IgG (207, 210), demonstrating their relevance as SLE 
autoantigens in vivo. Furthermore, the ability of microparticles to drive 
autoimmunity in sporadic patients may explain the flaring aspect of SLE, as 
temporal increases in microparticle production and/or release could overwhelm 
the available pool of DNASE1L3, allowing for persistence of unprocessed 
chromatin in circulation. 
 In addition to the patients whose antibodies bound to microparticles only in 
the absence of DNASE1L3, a further 40% of patients had IgG that bound to 
microparticles both before and after DNASE1L3 treatment. Because they contain 
a myriad of potentially immunogenic proteins, lipids, and nucleic acids, extensive 
characterization of the exposed surface antigens available to be bound by patient 
antibodies is required. One such molecule that is present on microparticle 
surfaces and is unaffected by DNASE1L3 is Sjögren’s-syndrome-related antigen 
A (SSA), antibodies against which are very strongly associated with both SLE 
and with disease-related complications (139-141). Furthermore, the apoptotic 
mechanisms that drive the export of chromatin from nuclei to microparticle 
surfaces remain uncharacterized, and additional in depth analysis of their 
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contents may yield insights to this somewhat enigmatic pathway. Notably, the 
R206C hypomorphic variant of DNASE1L3 has also been linked by GWAS to the 
development of scleroderma (160), which is often characterized by the presence 
of anti-centromere or anti-kinetochore autoantibodies (252). As evidenced by its 
ability to reduce the levels of the DNA-associated protein HMGB1 on 
microparticle surfaces, DNASE1L3 may also be capable of processing other 
potentially immunogenic molecules to prevent loss of tolerance in systemic 
scleroderma. 
 
Beyond SLE: DNASE1L3 and other diseases 
 Another outstanding question concerns the strong associations between 
human DNASE1L3 deficiency and the development of anti-C1q antibodies, which 
eventually results in hypocomplemetemia and likely contributes to the severity of 
SLE. C1q is normally involved in the clearance of apoptotic or other cellular 
debris, and strikingly has been shown to bind with increased avidity to such 
structures when they contain chromatin (153, 245, 246). Thus, we would 
hypothesize that in the absence of DNASE1L3, microparticles are more 
extensively bound by C1q. This may both deplete the pool of free C1q in 
circulation and may also contribute to activation of C1q-specific B cells, since 
C1q is now presented in conjunction with immunogenic molecules contained 
within microparticles. As these cells become activated and produce anti-C1q, the 
pool of C1q is further reduced, leading to impaired clearance of chromatin-loaded, 
unprocessed microparticles. Persistence of these microparticles would allow for 
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presentation to DNA-specific T and B cells, resulting in loss of tolerance and 
progression to SLE. Future experiments will investigate the potential impact of 
treatment with DNASE1L3 on the binding of complement to microparticles. In 
addition, determining whether anti-C1q antibodies are elevated in Dnase1l3 
knockout mice is key, albeit with the caveat that these antibodies do not lead to 
SLE development in mice as in humans (247). Finally, assessment of potential 
anti-C1q antibodies in sporadic patients will also be an important parameter, 
especially in the context of anti-microparticle immunity. 
 In addition, we are keen to investigate potential roles for DNASE1L3 in the 
regulation of cancer microparticles. As previously mentioned, microparticles have 
been implicated in the pathogenesis of cancer, both by enhancing metastasis 
and transformation through the delivery of various types of nucleic acids (184, 
186, 187, 200). Thus, DNASE1L3 may be an important host factor in limiting 
tumorigenesis, which will be tested in both spontaneous and injected mouse 
models. An alternative possibility is that the presence of DNASE1L3 prevents 
host interactions with oncogenic DNA or oncoproteins, which may impair the 
development of specific immune responses. More broadly, we would like to 
explore the potential usage of microparticles as a diagnostic surveillance tool. 
Because they contain mRNA in addition to DNA, we would like to perform RNA-
seq on microparticles isolated from various disease models, in particular cancer. 
These data can then be used to determine the cells of origin, so deviations from 
the steady state may be indicative of transformation. Such a liquid biopsy could 
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be easily applied to humans, and may be a way to improve early detection of and 
screening for cancer. 
 
DNASE1L3 activity as a marker for sporadic SLE 
 An intriguing finding in our sporadic cohort was the observation that 
diminished levels of circulating DNASE1L3 correlated with larger reductions in 
binding to microparticles after treatment with exogenous DNASE1L3. Although 
statistically significant, the biological impact is unclear, since individuals carrying 
the hypomorphic R206C variant have much greater reductions in activity without 
necessarily progressing to overt disease. In addition, the mechanisms driving 
differences in the activity of DNASE1L3 remain undiscovered. One possibility is 
the development of autoantibodies against DNASE1L3 itself, which will be tested 
in sporadic patients. Alternatively, preliminary data in the lab has suggested that 
DNASE1L3 expression is induced in macrophages in response to inflammatory 
stimuli, which may also explain variability between not only patients but also 
samples from the same patient. With the help of a collaboration with experts in 
the field of biostatistics, we are in the process of closely examining our data in 
conjunction with all measured parameters available. We are keen to determine 
whether DNASE1L3-sensitive chromatin binding correlates with data obtained in 
the clinic, which may lead to translational opportunities. In parallel, we are 
beginning to investigate patients longitudinally, which may allow for in depth 
assessment of the impact of disease flares, therapeutic interventions, and/or 
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inflammatory status on IgG binding to microparticles as well as the activity of 
DNASE1L3. 
 Our initial studies of sporadic patients were deliberately limited to those of 
European descent, with the aim being to specifically examine the impact of the 
R206C variant. We subsequently expanded our studies to include African 
American and Hispanic patients. Among the first group, we observed a greater 
fraction of patients who had no circulating anti-microparticle IgG compared to the 
cohort overall (~35% vs 20%). Given that disease in the latter populations tends 
to be more severe, anti-microparticle responses may represent an important and 
predictive disease parameter. Indeed, such a diagnostic test would be relatively 
straightforward to implement, and may lead to substantial quality of life 
improvements for patients who may be able to receive therapeutics 
prophylactically to prevent flaring as opposed to reactively. 
 
Therapeutic applications of DNASE1L3 
 One therapeutic option that we are eager to explore further concerns the 
administration of exogenous DNASE1L3, since we were able to restore normal 
levels of DNASE1L3 activity and consequently significantly delay the onset of 
anti-dsDNA autoantibodies by the use of an adenoviral vector in Dnase1l3-
deficient mice. A major drawback of this system, however, is that adenoviral 
vectors persist in hepatocytes for only 6-8 weeks, after which they are cleared by 
the immune system and subsequent administrations are ineffective due to 
memory responses. One solution is to take advantage of adeno-associated 
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viruses (AAVs), which do not trigger immune responses and can thus be used for 
prolonged expression in hosts (253, 254). Our lab has obtained two such AAVs 
encoding DNASE1L3, and both have proved effective at restoring DNASE1L3 
levels to those comparable to wild-type animals. It remains to be seen whether 
these AAVs are effective at ameliorating disease development, but if so such a 
treatment could be beneficial in sporadic SLE patients, especially since the 
cohort with DNASE1L3-sensitive antibodies also presented with lower 
DNASE1L3 activity. 
 In addition, our laboratory is working on the development of hyperactive 
DNASE1L3. As previously discussed, DNASE1 was modified to be actin-
independent and more potent catalytically by the substitution of six amino acids, 
four of which are already present in native DNASE1L3 (166). Using site-directed 
mutagenesis, the additional two substitutions have been introduced, and we are 
in the process of testing its efficacy. Although it may prove challenging due to the 
importance of the tertiary structure of the C terminus, we are also investigating 
potential modifications of DNASE1L3 that may allow it to persist for longer in 
circulation. Ultimately, we envision such a molecule as being a valuable 
therapeutic tool for the treatment of both inherited and sporadic SLE: a potent, 
long-acting injectable enzyme, the dosage of which can be modified based on 
well-defined longitudinal parameters. 
 We are also intrigued at potential roles for DNASE1L3 outside of 
circulation. As mentioned, it is expressed by hepatocytes, despite our 
observations that hematopoietic cells are responsible for the pool of DNASE1L3 
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in circulation. Consequently, it is possible that DNASE1L3 is also released into 
the digestive tract, as is the case for DNASE1. Given its potent activity and ability 
to process coated DNA, DNASE1L3 may play an important role in regulating the 
intestinal microbiome, potentially by limiting bacterial horizontal gene transfer. In 
addition, we have observed much more efficient adeno-associated viral 
transduction in Dnase1l3-deficient mice compared to wild-type animals, which 
may suggest that DNASE1L3 also plays a role in defense against DNA viruses. 
Characterization of the microbiome and viriome of Dnase1l3-deficient animals 
may prove illuminating. If DNASE1L3 does indeed have a role as an anti-viral 
molecule in particular, its administration may prove effective for the treatment of 
enveloped DNA viruses, such as herpesviruses or poxviruses. 
 
Conclusion 
 SLE is a very challenging disease to study for numerous reasons, chief 
among them being the heterogeneity of presentation between individual patients 
and/or flares. Indeed, it seems likely that what is collectively referred to as SLE in 
fact represents a collection of closely related disorders, wherein loss of tolerance 
occurs to a self-nuclear antigen. This can be followed by epitope spreading and 
the development of broader autoimmunity. Our studies have focused on 
DNASE1L3, since it is strongly tied to the very early and robust development of 
anti-dsDNA autoantibodies. These antibodies are predictive of both disease 
flaring and of disease severity between patients, underlying the urgent need to 
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understand more about how and why they are generated (255). Our data provide 
an example of one potential mechanism by which tolerance to self-DNA is lost. 
 In addition, it is possible that microparticles may be fundamentally 
involved in loss of tolerance to self-antigens that are not DNA-based. Given the 
large quantities of RNA and nuclear proteins they contain, their persistence in the 
bloodstream may also allow for delivery of additional autoantigens to reactive T 
or B cells. Further work is required to understand the extent of their contents and 
in what contexts they can contribute to the initial steps of autoimmunity. The 
complement system seems to be involved; preliminary work in the lab has found 
that microparticles are actively bound by multiple forms of complement. 
Furthermore, C1q deficiency represents an additional monogenic form of SLE in 
humans (155), suggesting that microparticle clearance is fundamentally required 
to prevent aberrant self-reactivity. 
 In conclusion, our data demonstrate that chromatin in microparticles is a 
potential self-antigen for autoreactive B cells, and that it is processed by 
circulating DNASE1L3 in both mice and humans. This digestion is both restricted 
to DNASE1L3 and is absolutely required to prevent the development of rapid 
anti-DNA responses that progress over time to full blown SLE. In addition, these 
results provide mechanistic insight to the observed associations between null 
and hypomorphic mutations in DNASE1L3 with inherited and sporadic SLE, 
respectively. More broadly, we have discovered a novel, cell-extrinsic means by 
which tolerance to a self-nucleic acid is enforced by DCs and, to a lesser extent, 
macrophages. The secretion of an enzyme that protects against autoimmune 
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development allows for unique opportunities for therapeutic intervention, as 
evidenced by our observation of delayed anti-DNA reactivity after re-expression 
of DNASE1L3 using an adenoviral vector. In particular, such a therapy may 
prove efficacious in the roughly 40% of patients who presented with extensive 
IgG binding to DNASE1L3-sensitive chromatin, especially as this same cohort 
also featured lower levels of DNASE1L3 activity. In addition, mutations in 
DNASE1L3 have been linked to other autoimmune diseases such as systemic 
scleroderma and HUVS, so delivery of exogenous DNASE1L3 may not be limited 
as a therapeutic tool to SLE alone.  
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Materials and Methods 
 
Dnase1l3-deficient animals 
All experiments were performed according to the investigator’s protocol, 
which was approved by the Institutional Animal Care and Use Committees of 
Columbia University and New York University. Mice with a targeted germline 
replacement of Dnase1l3 (Dnase1l3LacZ) were purchased from Taconic Knockout 
Repository (model TF2732). Backcrossing onto 129SvEvTac and C57BL/6 
backgrounds was performed for >10 generations, and pure strains were then 
intercrossed to yield Dnase1l3LacZ/LacZ knockout animals. Age-matched wild-type 
mice of the same backgrounds were bred in the same colony for use as controls. 
 
Deletion of STING or MyD88 in Dnase1l3-deficient mice 
STING-deficient mice (Tmem173gt/J) (256) and MyD88-deficient mice 
(Myd88tm1.1Defr/J) (257) were obtained from Jackson Laboratories, both on pure 
B6 backgrounds. Both strains were crossed to Dnase1l3LacZ B6 mice to produce 
double-heterozygous F1 litters, which were then backcrossed to Dnase1l3LacZ 
mice, thus generating Dnase1l3LacZ/LacZ mice that were either wild-type or 
homozygous null for Tmem173 or Myd88 (double knockout, dKO). To allow for 
infection-free survival of MyD88-deficient animals, breeder cages were 
administered trimethoprim and sulfadiazine-supplemented animal chow 
(Uniprim®, Harlan Teklad). Upon weaning, mice were switched to a normal diet. 
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Importantly, this diet had no effect on the development of autoimmunity in the 
littermate controls of dKO mice who lacked only DNASE1L3. 
 
Human subjects 
DNASE1L3-deficient HUVS patients 1 and 2 correspond to patients IV-4 
and IV-5 from family 1 described in (151). Patient 1 (14-year-old female) 
developed SLE with ANA and high anti-dsDNA 6 years ago. She was treated 
with rituximab (most recent dose in May 2012) and has been in clinical remission 
since (limited ANA, normal anti-dsDNA), although patient still presents with active 
uveitis. Patient 2 (12-year-old female) has not developed SLE (negative ANA, no 
anti-dsDNA) but presents with ongoing HUVS with moderate to severe vasculitis 
of the kidney. Their study was approved by the Ethics Committees of Ankara 
University (Turkey) and the Institutional Review Board of the University of Miami. 
Informed consents were obtained from the parents. 
Blood from patients with sporadic SLE and healthy controls was obtained 
from the NYU IRB-approved Rheumatology SAMPLE (Specimen and Matched 
Phenotype Linked Evaluation) Biorepository. All patients signed IRB-approved 
informed consent forms. All patients with sporadic SLE met at least 4 revised 
American College of Rheumatology criteria (12). Subjects were genotyped for 
DNASE1L3 rs35677470 using the TaqMan SNP genotyping kit (ThermoFisher). 
Three subjects (one healthy control and two SLE patients) were found to be 
heterozygous for the rare R206C hypomorphic allele. 
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Adenoviruses 
 The adenoviral vector encoding IFN-5 has previously been described 
(175). Human DNASE1L3 was cloned into an adenoviral vector and constructed 
by Welgen. Viral particles were produced and purified at Welgen, and were 
injected into Dnase1l3LacZ/LacZ mice intravenously at 0.5 or 1 x 1010 particles per 
mouse. No discernable differences were observed between the two doses. As a 
control, Dnase1l3LacZ/LacZ mice were injected with equivalent doses of adenoviral 
particles encoding GFP. 
 
ELISA 
 Anti-dsDNA and anti-RNA IgG titers were determined as previously 
described (72, 258). Plates were pre-coated with poly-L-lysine (0.05 mg/mL) for 2 
hours at room temperature, followed by coating with 0.1 mg/mL calf thymus DNA 
or yeast RNA (Sigma-Aldrich) as antigens. Anti-nucleosome IgG titers were 
assessed using plates coated with 1 g/mL of purified HeLa polynucleosomes 
(Epicypher). After coating, sera were added and incubated overnight. The 
amount of bound IgG was measured with an alkaline phosphatase (AP)-
conjugated goat anti-mouse IgG antibody (1:5000, Jackson ImmunoResearch). 
Antigen-specific IgG titers were determined using serial dilution of serum from a 
positive animal as a standard, and thus expressed as arbitrary units per volume. 
Anti-dsDNA IgG subtypes were measured as above using AP-conjugated 
antibodies to the indicated IgG subtypes (Southern Biotech). Total 
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immunoglobulin isotype levels were also determined as above, using AP-
conjugated antibodies to IgM, IgA, and IgG (Southern Biotech). 
 
ELISPOT 
 To detect antibody-secreting cells (ASC) specific to dsDNA, 96 well 
multiscreen plates (Millipore) were pretreated with 35% ethanol for 1 minute, 
coated with 100 g/mL calf thymus dsDNA (Sigma-Aldrich), then washed and 
blocked with a solution of 3% fetal calf serum (FCS) and 3% bovine serum 
albumin (BSA) in PBS. Single-cell suspensions of total splenocytes were plated 
in duplicate in six two-fold serial dilutions starting at 106 cells per well. Cells were 
incubated on the plate for 5 hours at 37oC. Plates were then washed and 
incubated with AP-conjugated goat anti-mouse IgG (1:5000, Jackson 
ImmunoResearch) overnight at 4oC. Spots were developed using the NBT/BCIT 
(Sigma-Aldrich) system and counted on an ImmunoSpot Series 1 ELISPOT 
analyzer (Cellular Technology Ltd). 
 
Anti-nuclear antibody staining (ANA) 
 Prefixed HEp-2 cells on glass slides were purchased from MBL Bion, and 
were incubated with mouse serum (1:100 dilution). This was followed by PE-
labeled goat anti-mouse IgG and DAPI. Images were captured on a confocal 
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Kidney IgG deposition and histopathology 
 Both kidneys were collected and fixed in 4% paraformaldehyde, 
dehydrated in 30% sucrose, then frozen in OCT (TissueTek). Frozen sections (5 
m) were stained with DAPI and PE-labeled goat anti-mouse IgG (eBioscience), 
then visualized by confocal microscopy as above. 
 Sections of formalin-fixed kidneys (2 m) were stained with hematoxylin 
and eosin, then evaluated by a pathologist (V. D’Agati) blinded to sample identity. 
Mesangial and endocapillary proliferation, leukocyte infiltration, glomerular 
deposition, and apoptosis were scored individually on a scale from 0 (none) to 4 
(severe), then added to produce a cumulative score. The percentage of cortical 
parenchyma with interstitial inflammation was also determined. Images were 
captured on a Zeiss AxioImager upright microscope and processed by AxioVision 
software (Carl Zeiss). 
 
Germinal center immunohistochemistry 
 To visualize germinal center reactions, frozen spleen sections (5 m) were 
stained with PE-labeled anti-mouse B220 (eBioscience) and biotin-conjugated 
peanut agglutinin (PNA; Vector Laboratories) followed by FITC-conjugated 
Streptavidin (eBioscience). Sections were then visualized by confocal 
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Flow cytometry 
 Suspensions of peripheral blood leukocytes or splenocytes were 
subjected to red blood cell lysis and were subsequently washed and stained with 
directly conjugated fluorescent antibodies to the relevant surface markers 
(eBioscience). LacZ expression was analyzed as in (259). Single cell 
suspensions were washed and resuspended in HBSS containing 1 mM HEPES 
and 2% FCS. These cells were incubated for 20 minutes at 37oC, then were 
mixed with pre-warmed 2 mM fluorescein di--D-galactopyranoside (FDG, 
Sigma-Aldrich) in a hypotonic solution for 1 minute. Immediately thereafter, cells 
were placed on ice and washed with ice-cold HBSS buffer. Endogenous 
lysosomal -gal activity was blocked by 0.3 mM chloroquine diphosphate. After 
loading with FDG, cells were stained for surface markers as above, then 
analyzed by flow cytometry. Data was collected on either LSR II (BD) or Attune 




 Cloned open reading frames (ORFs) of human DNASE1 (NCBI: 
NP_005214.2) and DNASE1L3 (NCBI: NP_004935.1) were subcloned into the 
pMSCV-IRES-GFP (pMIG) retroviral expression vector. The constructs for 
DNASE1L3 variants were generated using the Q5 site-directed mutagenesis kit 
(NEB), including the R206 to C substitution, the C-terminal truncation (amino 
acids 282-305), and the insertions of hexahistidine tags between aa 282-283 
 
 - 113 - 
(His-preCT) or between aa 305 and the stop codon (His-CT). The resulting 
constructs or the empty pMIG vector were used as plasmids for the transient 
transfection of HEK293 cells using the TransIT-293 transfection reagent (Mirrus). 
Equal transfection efficiency was determined by GFP expression, as measured 
on an Accuri C6 tabletop flow cytometer (BD Biosciences). To avoid 
contamination with bovine DNASEs, transfection was performed in medium 
containing 15% KnockOUT serum supplement (Thermo Fisher) in lieu of FCS. 
Transfected cells were cultured for 48 hours, and the supernatants were 
collected, filtered, supplemented with 4 mM CaCl2 and 4 mM MgCl2, then frozen 
in aliquots. 
 
Analysis of DNASE1L3 activity 
 To measure the digestion of liposome-coated DNA, pMIG plasmid DNA 
was pre-incubated with N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium 
methyl-sulfate (DOTAP) (Roche) in HBSS according to the manufacturer’s 
protocol. 1 ng of naked or DOTAP-coated plasmid per reaction was incubated 
with an equal volume of DNASE-containing supernatants or sera for 60 minutes 
at 37oC, for a final reaction volume of 2 L. The amount of DNA remaining after 
digestion was measured by qPCR with GFP-specific primers and expressed as a 
percentage of input DNA using a calibration curve generated from serial plasmid 
dilutions. 
 For the measurement of relative DNASE1L3 activity in vivo, the digestion 
was performed for 10 minutes using 1 L of mouse or human serum or plasma, 
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again in a final reaction volume of 2 L. After qPCR, the amount of DNA 
remaining post-digestion was converted to a percentage of DNASE1L3 activity 
using a calibration curve generated from serial dilutions of multiple wild-type 
serum or plasma samples. 
 Purified human polynucleosomes from HeLa cells (Epicypher) or purified 
Jurkat cell DNA (2 ng/reaction) were incubated with an equal volume of DNASE-
containing supernatants for 15 minutes at 37oC in a total volume of 2 L. The 
amount of remaining DNA was measured by qPCR with primers specific for 
human genomic Alu repeats and expressed as a percentage of input DNA using 
a calibration curve generated from serial DNA dilutions. 
 
Hematopoietic reconstitution 
 To reconstitute the hematopoietic system of recipient mice, 2 x 106 total 
BM cells were isolated from WT or KO mice on the 129 background. Cells were 
transferred into lethally irradiated WT and KO recipients on the B6 background, 
which has the same MHC haplotype. Reconstitution was tracked by staining for 
the 129 donor strain specific CD229.1 marker. An additional set of experiments 
was performed using WT recipients only. BM cells from WT or KO mice on the 
(129xB6) F1 background were transferred into lethally irradiated congenic 
(129xB6.SJL) F1 recipients. Reconstitution was tracked by staining for the 
B6.SJL recipient strain specific CD45.1 leukocyte marker. In all analyzed 
chimeras, the donor contribution was greater than 95%. 
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Specific depletion of cell populations 
 Rag1-deficient mice were purchased from Jackson Laboratories. To 
deplete dendritic cells (DCs), animals with a Cre-inducible diphtheria toxin 
receptor (iDTR) allele (260) were crossed with the DC-specific Cre deletion strain 
Cd11c-Cre (261). The resulting Cd11c-Cre/iDTR mice were administered 
diphtheria toxin (DTX) at a dose of 20 ng per gram of body weight every other 
day for two weeks as described (262). Efficient DC depletion was confirmed by 
flow cytometry at the endpoint, and minimal effects of DTX were observed on DC 
populations in mice lacking iDTR. To deplete macrophages, B6 mice were 
injected intraperitoneally with 150 g per gram of body weight of macrophage 
colony-stimulating factor 1 receptor (Csf1r) blocking antibody (clone AFS98, 
(263)) purified from a hybridoma as previously described (264). Depletion was 
confirmed by flow cytometry. For macrophage depletion by clodronate, mice 
were injected intravenously with a single dose (200 L) of clodronate liposomes 
(5 mg/mL) or control liposomes containing PBS (obtained from 
ClondronateLiposomes.com). Depletion was again confirmed by flow cytometry. 
 
Molecular modeling 
 ZEGA global sequence alignment of DNASE1 (PDB:2DNJ, chain a) and 
DNASE1L3 (Uniprot:Q13609) was performed as previously described (265). 3D 
structures were visualized and analyzed with Internal Coordinate Mechanics 
Software (ICM-Pro Molsoft LLC, La Jolla, CA). Amino acids in the DNASE1 
crystal structure 2DNJ, chain a contacting DNA were identified by selecting 
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amino acids exhibiting any atom center within a 5 Å radius of any atom center in 
the DNA. Prediction of the structure of the isolated DNASE1L3 C-terminus (282-
SSRAFTNSKKSVTLRKKTKSKRS-305) and the C-terminus and His mutants in 
the context of the whole DNASE1L3 protein was performed using the Biased-
Probability Monte Carlo algorithm, which was shown to be as accurate as 
experimental structure determination for short peptides (266). Homology 
modeling of DNASE1L3 was performed as previously described (267). 
 
Generation, isolation, and analysis of microparticles 
 Microparticles from Jurkat cells were generated as previously described 
(210). In brief, 1 mM staurosporine (STS, Sigma-Aldrich) was added overnight to 
Jurkat cell cultures. Cells were harvested and collected by centrifugation for 5 
minutes at 300 x g. The supernatants were collected and centrifuged at 22,000 x 
g for 30 minutes to pellet microparticles. Pellets were resuspended in sterile PBS 
and then analyzed on an Accuri C6 tabletop flow cytometer (BD Biosciences) to 
determine absolute numbers and ensure >95% enrichment. Where indicated, 
microparticles (105 per L) were incubated with an equal volume of DNASE-
containing transfection supernatants for 1 hour at 37oC. 
 To generate mouse microparticles, primary splenocytes were cultured for 
2-3 days with 50 ng/mL phorbol 12-myristate 13-acetate (PMA) and 2 g/mL 
ionomycin (Sigma-Aldrich). The resulting cultures of activated, proliferating 
splenocytes were treated with 1 mM STS overnight, and microparticles were 
collected and analyzed as for Jurkat cells. Weekly, 107 of these microparticles 
 
 - 117 - 
were injected intravenously into wild-type female 129 mice who had previously 
been administered either PBS or 5 x 109 IFN5 adenoviral particles. After four 
instances of microparticle injection, the mice were analyzed one week later. 
 To isolate microparticles from human plasma, blood was collected in tubes 
containing ethylenediaminetetraacetic acid (EDTA), and blood cells were 
removed by centrifugation at 2,000 x g for 10 minutes at 4oC. In some 
experiments, a second centrifugation step at 3,000 x g for 10 minutes at 4oC was 
used to deplete platelets as previously described (205). The resulting plasma 
(either fresh or stored at -80oC) was centrifuged at 22,000 x g for 30-60 minutes 
to pellet microparticles, and the supernatant was used to measure DNASE1L3 
activity and antibody binding specificities. Microparticles from murine plasma 
were isolated as well. Mice were euthanized and immediately exsanguinated by 
cardiac puncture into tubes containing heparin. Plasma was then isolated by 
centrifugation at 2,000 x g for 10 minutes at 4oC, and then centrifuged at 22,000 
x g for 30 minutes to pellet microparticles. Plasma microparticles were 
resuspended in sterile PBS and stained for CD42b and CD235a (human) or 
CD41 and Ter119 (mouse) to exclude platelets and erythrocyte debris, 
respectively. Stained microparticles were assessed on an Accuri C6 tabletop flow 
cytometer (BD Biosciences) to count absolute numbers of the unstained fraction. 
 To test the ability of mouse serum to digest microparticle DNA, Jurkat 
microparticles (5 x 105 per L) were incubated with an equal volume of serum for 
1 hour at 37oC in a final reaction volume of 10 L. Human plasma was tested 
using the same protocol, with the exception that microparticles (5 x 105 per L) 
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derived from mouse splenocytes were used instead. The DNA content of Jurkat-
derived microparticles, human plasma microparticles, and total human plasma 
was determined by qPCR for human genomic Alu repeats. The DNA content of 
mouse splenocyte-derived microparticles, murine plasma microparticles, and 
total murine plasma was determined by qPCR for mouse genomic B1 repeats. In 
both cases, raw qPCR data was converted into the amount of genomic DNA 
remaining after digestion using calibration curves derived from serial dilutions of 
the respective genomic DNA. Data were then expressed either as the percent of 
input DNA or, in conjunction with our counting of absolute microparticle numbers 
through the use of the Accuri, as amount of DNA per microparticle. 
 
Persistence of microparticles in vivo 
 6 x 106 Jurkat cell-derived microparticles were injected intravenously per 
mouse into wild-type mice. Recipients were euthanized at the indicated time 
points, and their tissues were analyzed by qPCR for the presence of human DNA 
using primers specific for the Alu human genomic repeat. 
 
Staining of microparticles 
 For surface staining, 2.5 x 105 native or DNASE-treated Jurkat cell-derived 
microparticles were incubated with either purified anti-DNA/histone 2a/2b mAb 
PR1-3 (10 g/mL), mouse sera (1:10 dilution), purified 9G4-positive Fab 
fragments derived from human patients fused to the Fc region of mouse IgG (240, 
241, 268), or hybridoma supernatants (PR1-3, PL2-8 (anti-DNA/histone), PL9-11 
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(anti-DNA) (269, 270), and 3H9 (anti-DNA) (271)) for 30 minutes at 4oC. 
Hybridomas were kindly provided by M. Shlomchik (University of Pittsburgh), 
while 9G4-positive antibodies were generously provided by G. Silverman (New 
York University) and I. Sanz (Emory University). Stained microparticles were 
washed by centrifugation at 22,000 x g for 30 minutes, and were then incubated 
with PD-labeled goat anti-mouse IgG secondary antibody (eBioscience) at 1:200 
for 30 minutes at 4oC. Microparticles were then analyzed by flow cytometry 
without further washing on an Attune NxT flow cytometer (ThermoFisher). 
Staining with human plasma or sera was performed as above at a 1:20 dilution, 
with a PE-labeled goat anti-human IgG secondary antibody (eBioscience). 
 
Statistical analysis 
 In the interest of robust statistical analysis, normal distribution of values 
was not assumed (272). Unless otherwise indicated in figure legends, data were 
displayed as medians with a range of indicated values. Statistical significance 
was calculated by the nonparametric Mann-Whitney test. Significance is 
indicated throughout as follows: *=p ≤ 0.05; **=p ≤ 0.01; ***=p ≤ 0.001. 
 
PCR primer sequences 
GFP: 
FW: AAGTTCATCTGCACCACCGG; RV: GCGCTCCTGGACGTAGCCTT 
Human Alu repeats: 
FW: TCACGCCTGTAATCCCAGCA; RV: AGCTGGGACTACAGGCGCCC 
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Mouse B1 repeats: 
FW: GGGCATGGTGGCGCACGCCT; RV: GAGACAGGGTTTCTCTGTGT 
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